



How effective is European merger control?

Tomaso Duso^{a,*}, Klaus Gugler^b, Burcin B. Yurtoglu^c

^a Duesseldorf Institute for Competition Economics (DICE), Heinrich-Heine University and Wissenschaftszentrum Berlin (WZB), University Duesseldorf, Universitaetsstr. 1, D-40225 Duesseldorf, Germany

^b WU (Vienna University of Economics and Business), Austria

^c WHU—Otto Beisheim School of Management, Germany

ARTICLE INFO

Article history:

Received 6 October 2008

Accepted 28 April 2011

Available online 13 May 2011

JEL classification:

L4

K21

G34

C2

L2

Keywords:

Merger control

Remedies

European Commission

Event studies

ABSTRACT

This paper applies an intuitive approach based on stock market data to a unique dataset of large concentrations during the period 1990–2002 to assess the effectiveness of European merger control. The basic idea is to relate announcement and decision abnormal returns. Under a set of four maintained assumptions, merger control might be interpreted to be effective if rents accruing due to the increased market power observed around the merger announcement are reversed by the antitrust decision, i.e. if there is a negative relation between announcement and decision abnormal returns. To clearly identify the events' competitive effects, we explicitly control for the market expectation about the outcome of the merger control procedure and run several robustness checks to assess the role of our maintained assumptions. We find that only outright prohibitions completely reverse the rents measured around a merger's announcement. On average, remedies seem to be only partially capable of reverting announcement abnormal returns. Yet they seem to be more effective when applied during the first rather than the second investigation phase and in subsamples where our assumptions are more likely to hold. Moreover, the European Commission appears to learn over time.

© 2011 Elsevier B.V. All rights reserved.

1. Introduction

This paper aims to provide econometric evidence on the effectiveness of merger control decisions in the European Union (EU). This seems to be both necessary and timely. From an academic perspective, there is a lively on-going discussion among antitrust scholars as to whether there is any need for a competition policy at all, as witnessed by the discussion spurred by Crandall and Winston's (2003) and Baker's (2003) papers. In particular, merger control institutions are repeatedly under criticism: they are ineffective and do not deter anticompetitive conduct (Crandall and Winston, 2003), they destroy synergistic efficiencies by unnecessarily intervening in the market place (Aktas et al., 2004), are protectionist (Aktas et al., 2007), are relatively open to capture (Evans and Salinger, 2002), might not be the best instrument to prompt technological progress (Carlton and Gertner, 2003), or they are too lenient and allow anticompetitive mergers to go through (Kim and Singal, 1993).

From the policy standpoint, throughout the last decade there has been a clear shift in merger control to consider remedies as a superior policy instrument if compared to outright prohibitions. Remedies are supposed to function as a surgery treatment in that they effectively tackle the market power concerns potentially raised by mergers without

* Corresponding author.

E-mail addresses: duso@dice.uni-duesseldorf.de (T. Duso), Klaus.Gugler@wu.ac.at (K. Gugler), burcin.yurtoglu@whu.edu (B.B. Yurtoglu).

destroying efficiency enhancing synergies.¹ In this instance, the European experience is enlightening. The European Commission cleared most of the over 4200 notified mergers since 1990 without commitments (around 90%), as they presumably do not pose a threat to competition. Nonetheless, few major mergers have been completed without some conditions and obligations being offered by the parties and implemented by the agency, such as divestitures, provision of access, termination of agreements, or other behavioral requirements. More than 60% of phase 2 decisions were cleared compatible only with commitments; yet only 20 mergers were blocked between 1990 and 2009.² Moreover, significantly fewer proposed mergers have been blocked in recent years, following the overruling of three of the Commission's prohibitions by the European Court of Justice (*Airtours/First Choice*; *Schneider/Legrand*; and *Tetra Laval/Sidel*), which were under the media spotlight and triggered major institutional changes in European antitrust.³ A similar evolution of merger policy is reflected in the American experience. The Federal Trade Commission (FTC) and the Department of Justice (DOJ) have also been increasingly making use of remedies in merger control decisions during our sample period (see Fig. 1).⁴ However, unlike the European Commission, prohibitions have been intensively employed in the US, especially during the last 3 years of our sample.

Despite the economic importance and intense policy debate, there is almost no systematic econometric evidence on whether merger policy achieves what it is supposed to achieve, namely to “protect and restore effective competition”, nor on whether remedies are indeed the most appropriate instrument. We analyze the effects of merger control decisions using a sample of 151 mergers scrutinized by the European Commission between 1990 and 2002. We use evidence from the stock markets as an independent and ex-ante assessment of the competitive consequences of the mergers and the EU Commission's decisions. In the first step, we use a standard event study methodology to compute cumulative average abnormal returns (CAARs) around relevant events for both merging firms and for their rivals, which have been identified by the Commission itself and retrieved from its published files. Our starting point is that CAARs around the merger announcement should capture the merger's competitive impact, while CAARs around the announcement of the Commission's decision should measure the merger policy's effects (e.g. *Eckbo and Wier, 1985*).

Clearly, in order to make this inference, one has to account for the market expectations regarding the merger control procedure's outcome. This is one of the first novelties of our approach, which we believe increases the reliability of CAARs as a measure of the competitive effect of a merger and a merger decision. We propose using the observable characteristics of a merger to estimate the probability of a particular antitrust intervention, and correct our profitability measures (i.e. CAARs) accordingly. In doing so, we must rely on the assumption that, on average, the market does not perfectly foresee the Commission's decisions.⁵

The final step constitutes the major innovation of our approach and lies in relating these expectation-corrected stock market reactions by using regression analysis to assess the effectiveness of merger control. The intuitive basic idea is that, under a set of assumptions that we thoroughly discuss, anticompetitive rents generated by the merger and measured around its announcement should be dissipated by the antitrust authority decision, if this is effective. Hence, we expect a negative relation between decision CAARs and announcement CAARs. In addition, the design of our test gives us a potential benchmark for a remedy's effectiveness and, simultaneously, a robustness check for our approach: outright prohibitions should dissipate all rents that would have been generated by the merger and restore effective competition. Thus, we expect a coefficient of minus one in this case.

Reassuringly, in all regressions and specifications, we get a negative coefficient in the case of prohibitions, which is almost never significantly different from minus one. Furthermore, our findings also suggest that remedies are on average only partially capable of reverting the rents generated around the merger announcement. According to our framework, we interpret this result as remedies not being able to solve anticompetitive concerns on average. Yet, we can qualify this finding. Remedies seem to be more effective when the anticompetitive concerns are not too severe, and when applied during the first rather than the second investigation phase. Moreover, the European Commission appears to learn over time, since remedies seem to be more effective when applied in “remedy-intensive” industries, i.e. industries where many remedies have been applied before.

A set of four maintained assumptions are the foundation of our theoretical framework. To verify the validity of our inference, we present a large number of robustness checks, which should account for the potential failure of each of these

¹ This tendency in the policy arena is reflected by several recent reports on remedies by the world's major antitrust jurisdictions (*FTC, 1999; OFT, 2005; DG Comp, 2005*) and international organizations (*OECD, 2004*), as well as the issuing of remedy guidelines (*FTC, 1999; European Commission, 2001; U.S. Department of Justice, 2004*). See *Davies and Lyons (2007)* for an excellent overview of the topic.

² See <http://ec.europa.eu/competition/mergers/statistics.pdf> for constantly updated statistics on EU merger control.

³ These events made it very difficult for the Commission to block further mergers. Indeed, no merger was blocked in 2002, 2003, 2005, 2006, and 2009 and only one was blocked in 2004 and 2007, respectively.

⁴ We thank Joe Clougherty and Jo Seldeslachts for providing us with the US data. While it seems that frequency of an action is higher in the EU than in the US, this is surely due to the kinds of mergers under scrutiny in the two jurisdictions. In the EU, only large mergers are notified to the Commission, the smaller ones being under the jurisdiction of the national authorities. Instead, the DOJ and FTC are in charge of all US mergers which are above specific thresholds.

⁵ This seems a reasonable assumption supported by anecdotal evidence. On February 17, 2010, the DOJ approved the alliance between British Airways (BA) and American Airlines (AA), provided that the parties make four pairs of London Heathrow take-off and landing slots available for up to 10 years to transatlantic competitors. The companies' share price as well as that of their partners (Iberia and Finair) sharply increased. Reuters news agency stated: “Four daily slot pairs is better than analyst expectation of six and significantly better than the 32 that the alliance was asked to give up back in 2001, the last time BA/AA applied for immunity.” The market updated its belief about the profitability effect of the antitrust decision.




Fig. 1. Frequency of merger control interventions: EU and USA.

assumptions. In particular, we assume that after correcting for the market expectations about the merger control procedure, rivals' abnormal returns around the first rumor about the specific merger can be taken as an indication of the merger's competitive effects.⁶ Being conscious that it might be restrictive to ignore that announcement effects intermingle other information, we are very careful to provide several pieces of evidence to support our results. Our main results are confirmed and reinforced in those subsamples, where our assumptions are more likely to hold.

The approach based on stock market data, despite its difficulties, has several major advantages if compared to the use of other data sources. First and most notably, it allows one to disentangle the merger from the decision effects, whereas looking at the effects on firms' accounting profits just allows one to measure the net effect. Second, it does not require one to define the time span along which the merger effects should be observed. Finally, it allows one to analyze blocking decisions and avoid a potential censoring problem due to the fact that the impact of a merger is only observed if the merger takes place.

The paper proceeds as follows. Section 2 presents a short overview of the literature on the assessment of competition policy. Section 3 briefly presents the institutional background of EU merger control. Section 4 discusses our main

⁶ The casual reading of the daily business press provides several examples in line with this main assumption. On November 12, 2009, two large mergers were announced of which commentators viewed one as clearly anticompetitive and the other as clearly pro-competitive. British Airways (BA) and Iberia announced a merger, whereby BA shareholders should end up with 55% and Iberia shareholders with 45% of the new company. The two companies would create the world's third largest airline by revenue after Air France-KLM and Lufthansa. The share prices of the involved companies and their rivals increased the days surrounding the announcement: BA's and Iberia's share prices rose by around 10% and 15%, respectively. Similarly, their main rivals' shares rose by around 7% (Lufthansa) and 6% (Air France-KLM), while the peer market indexes only rose by around 1% in that time period. Many commentators viewed this merger as being anticompetitive, mainly on the grounds that the Oneworld alliance (i.e. BA's alliance) already had a "tight grip" on the Heathrow airport, and the merger would make matters worse particularly concerning take-off and landing slots (see e.g. AFX News, November 13, 2009). The observed announcement "abnormal returns" are consistent with this interpretation. The same day, Hewlett-Packard (HP) announced the takeover of 3Com, paying a 40% premium over the pre-announcement share price. Despite that, HP shares also rose by around 2%, whereas the Dow Jones approximately remained flat. The deal was widely seen as being aimed at Cisco Systems, the leader in computer networking (see e.g. Jordan Robertson, November 12, 2009, AP Technology, "HP's 3Com takeover marks a shot at Cisco"), since the biggest companies that provide corporate computing infrastructure try to become "one-stop technology shops". Thus, 3Com assets are complementary to HP's and allow HP to offer more integrated solutions to customers. Cisco lost 2% in value on the day of the announcement of the deal, precisely in line with the idea that the stock market believed it to be a pro-competitive takeover.

methodology, hypotheses, and maintained assumptions as well as robustness tests. In Section 4, we introduce the data and some summary statistics, and Section 5 presents our main results as well as our robustness checks. Section 6 sums up and concludes. Appendix A formally describes the event study methodology, Appendix B explicitly spells out our approach to correct the profitability measures for the market expectations about the antitrust decision, and Appendix C provides a graphical exposition of our theoretical framework.

2. Literature review

The evaluation of competition policy effectiveness has attracted academic and policy interest since the early 1970s. Earlier studies evaluated the ex-post effectiveness of merger control decisions and, in particular, ordered remedies in the USA using a case-by-case approach. Elzinga (1969), Pfunder et al. (1972), and Rogowsky (1986) use a methodology that is based on classifying ordered remedies as successful, sufficient, deficient, or unsuccessful depending on whether they fulfill certain criteria. While Elzinga (1969) argues that only one out of ten cases can be classified as successful or sufficient, the success rate by Rogowsky (1986) increases to 40%.

More recent analyses are reported in two studies commissioned by antitrust authorities of the US and EU. The report commissioned by the FTC (1999) reviews 35 divestiture orders from 1990 to 1994. Based on interviews, the study finds that most divestitures appear to have created viable competitors in the concerned market (28 out of 37). A higher percentage of divestitures (19 out of 22) were successful when they involved the sale of an entire ongoing business. The Directorate General for Competition of the European Commission also recently published an in-house study on merger remedies (DG Comp, 2005). It reviews the design and implementation of 85 different remedies adopted in 40 decisions by the European Commission between 1996 and 2000. The analysis is also done by means of interviews with the committing parties or sellers, licensors and grantors, the purchasers or buyers, licensees and grantees and the trustees. More than half (57%) of the analyzed remedies were considered to have been effective, 24% were only partially effective since they raised design or implementation issues that were not resolved during implementation, 7% were clearly “ineffective”, and 12% have been categorized as “unclear” remedies. Interestingly, phase 1 remedies were considered more effective than phase 2 remedies. This may be due to the generally higher complexity of second phase cases. Phase 2 investigations differ from phase 1 investigations in view of the drastically different timeframes involved (six weeks vs. four month) and that remedies proposed in phase 1 need to be clear-cut and straightforward. While certainly informative, the fact that these divestiture studies only use qualitative information (interviews) for a small number of cases limits their generality.

Ellert (1976) is the first study that looks at the valuation effects of anti-merger complaints on firms' stocks. He does not, however, consider the impact on rivals' stock returns, which was first proposed by Eckbo (1983), Stillman (1983), and Eckbo and Wier (1985). Although they find significantly positive abnormal returns for rival firms, they argue that this positive valuation effect may be due to positive information released by the merger: the merger announcement is good news from the rival firms' perspective, because it makes them (or the market) aware of real profit opportunities that were so far unknown. In particular, the paper by Eckbo and Wier (1985) makes the point that the only pattern consistent with a merger being anticompetitive is positive abnormal returns to rivals at a merger's announcement and negative abnormal returns at the antitrust complaint. They do not find evidence for such patterns, and they therefore reject the collusion hypothesis in favor of their information hypothesis.⁷ While our approach makes use of the same kind of logic, we improve substantially on the identification issue as we explicitly relate announcement and decision abnormal returns by means of regressions to make more precise inference about the effectiveness of remedies. Moreover, different from these earlier studies, we also correct for the market expectations about the merger control inquiry, which improves the identification of the merger competitive effect.

The papers most closely related to the present one, in terms of data and research focus, are probably Duso et al. (2007a) and Aktas et al. (2004, 2007). Using the same sample of EU mergers as utilized in this paper, Duso et al. (2007a) show that for at least half of the mergers rival firms benefit after the merger is announced, i.e. they can be considered to be anticompetitive. By contrasting the markets' reactions with the actual Commission's decisions, they define type I errors (i.e. pro-competitive mergers blocked or modified by the authority) and type II errors (i.e. anticompetitive mergers unconditionally cleared). Using probit regressions, they show that procedural issues, market definition, as well as the merging firms' country and industry of origin play crucial roles in predicting both kinds of errors, while lobbying activities by firms do not. The fact that the Commission made mistakes is a first hint about the potential “non-effectiveness” of its policy. However, Duso et al. (2007a) did not look at the effects of the decisions. Hence, our study should be seen as the natural next step in understanding the effectiveness of EU merger policy.

Aktas et al. (2004) look at 602 EU Commission decisions involving 1070 firms and document significant abnormal returns for the target firms and smaller and less significant bidder abnormal returns. As does this paper, they also estimate abnormal stock price reactions to phase 1 and phase 2 decisions, and find that outright prohibitions are associated with

⁷ These early studies have been challenged by McAfee and Williams (1988) and Werden and Michael (1989). They argue that the failure to detect market power may be due to rivals being large conglomerates that receive only a small portion of their profits from the relevant market. They also argue that the existence of effective merger control may have had a deterrent effect on certain types of attempted mergers, which cannot be measured with this methodology. Finally, they claim that event studies of individual mergers are unreliable because stock prices provide very noisy information about the collusive effects of mergers. Eckbo (1989) offers a rebuttal to most of these criticisms.




Fig. 2. The EU merger control process.

negative abnormal returns and approvals subject to conditions are relatively good news. However, they do not look at the effects on rival firms and they do not make inferences about the quality of antitrust. In a follow-up paper, Aktas et al. (2007) look more closely at the issue of whether the Commission decisions can be interpreted as being protectionist in the sense of protecting European firms from foreign competitors. They enlarge their previous dataset by estimating CAARs for rivals as well. Some of their results seem consistent with decisions increasing consumers' surplus. Yet they find that the likelihood of an intervention by the EU Commission is higher when the merger is proposed by a bidder from outside the EU and has a negative effect on European rivals. They interpret this result as the European merger control being protectionist. Clearly, this paper focuses on one important yet very peculiar aspect of merger control. We therefore aim to provide a broader framework, which can be more generally used to evaluate the effectiveness of merger policy.

To sum up, the evidence on merger control decisions is rather mixed. Studies of remedies in a case-by-case approach point to the superiority of structural over behavioral remedies, and possibly phase 1 over phase 2 remedies (DG Comp, 2005), but leave doubt about their general effectiveness. Theoretical arguments underline this conclusion.⁸ Most studies based on stock market reactions find positive effects of mergers for rival firms, yet the interpretation of this result differs. Some authors interpret this as being consistent with the information revelation hypothesis (e.g. Eckbo, 1983; Eckbo and Wier, 1985), while other authors interpret it as consistent with the market power hypothesis (e.g. Simpson, 2001; Duso et al., 2007a). In what follows, we try to resolve these ambiguities.

3. Institutional features

Merger control in the EU began with the European Communities Merger Regulation (ECMR), which came into force on September 21, 1990.⁹ According to the ECMR, a merger has community dimension, hence it is under the jurisdiction of the Commission, if "it takes place between firms with a combined worldwide turnover of at least 5 billion Euros and a turnover within the European Economic Area of more than 250 million Euros for each of at least two of the undertakings unless each undertaking achieves more than 2/3 of its aggregate Community turnover within one and the same member state." This definition also includes mergers between firms that produce outside of Europe and sell in Europe. If necessary, a merger can be referred back to the member states for review.

Art. 2(3) of the ECMR states that: "A concentration, which creates or strengthens a dominant position as a result of which effective competition would be significantly impeded in the common market or in a substantial part of it, shall be declared incompatible with the common market." This is commonly referred to as the dominance test (DT). The DT constitutes an important difference to the SLC (substantial lessening of competition) test, which is used by US competition authorities. Some observers (e.g. Lyons, 2004) argue that the DT puts unnecessary weight on the concept of dominance in cases where the most important issue concerns the significant impediment of effective competition. The new merger regulation, which was applicable from May 1, 2004, focuses on a merger's impact on competition.

These regulations define the legal steps, which serve to control concentrations between undertakings (see Fig. 2), and which provide important dates for our event study. After receiving notification of the concentration, the Commission has 25 working days to assess whether the concentration is compatible with the common market (phase 1).

The Commission can either clear the proposed concentration unconditionally (Art. 6.1.b), it can decide to let it go through after verifying that the commitments and obligations proposed by the undertakings can effectively restore competition (Art. 6.2), or it can decide that the proposed concentrations raise serious doubts as to their compatibility with the common market (Art. 6.1.c) and, therefore, a more in-depth analysis is needed (notice that the Commission cannot outrightly block a merger after the phase 1 investigation). In this case, the Commission opens the so-called phase 2, which consists of 90 working days, during which an in-depth investigation is carried out. In general, the Commission makes use

⁸ Motta et al. (2003) enumerate the pros and cons of the different kinds of remedies (i.e. structural and behavioral) used by the European Commission. While in principle they favor the use of structural remedies to clear problematic mergers, they also point to information asymmetries and incentive problems, as well as to the increased possibility of pro-collusive effects of divestitures. Davies and Lyons (2007), based on their empirical study using simulations, suggest that for global mergers behavioral remedies might be preferred in national markets especially when a national authority can monitor their application. Farrell (2003) argues that the effectiveness of structural remedies may suffer from inadequate buyers, "over" (or "miss") fixing and the discounting of merger efficiencies. Cabral (2003) instead supports the superiority of structural remedies.

⁹ Council Regulation (EEC) No. 4064/89 was amended by Council Regulation (EC) No. 139/2004 on the control of concentrations of undertakings that entered into force on January 20, 2004. Commission Regulation (EC) No.802/2004 implements the Council Regulation (EC) No. 139/2004.

of the entire available time, given the problematic nature of these cases, after which it has to come to a final decision: block the merger (Art. 8.3), let it through unconditionally, or clear it with commitments and obligations (Art. 8.2).

Looking at Fig. 2, there are three events which are important for our empirical analysis. The first is the merger announcement, which we define as the first merger-specific rumors appearing in the press, and which should help us identify the market's assessment of the merger's competitive effects. The other two relevant events are the phase 1 and the phase 2 decision dates, which should help us identify the effect of the merger control procedure.

4. Hypotheses, methods, and robustness tests

This section develops the core framework of our analysis. The central idea of this paper is that an effective merger control should dissipate anticompetitive rents generated by the merger. Therefore, merger control effectiveness can be assessed in several steps: (i) theoretically identify anticompetitive rents, (ii) empirically quantify the rents generated by mergers and merger control decisions, and (iii) relate these measures by means of regression analysis to assess the extent of rent reversion achieved by different merger control tools.

Next, we separately describe these steps, explicitly spell out the framework's founding assumptions, and discuss our empirical predictions and how they might be affected if our maintained assumptions fail to hold. Throughout the paper, we assume that stock markets are efficient in a semi-strong form, i.e. that the prices of stocks reflect all publicly available information. We share this basic hypothesis with the entire literature using the event study methodology; hence we will not try to give an appraisal of this central assumption.

4.1. Defining the competitive effects of mergers

Oligopoly theory (e.g. Stigler, 1950) predicts that when firms merge they potentially generate two externalities on rival firms: a positive externality due to the merger's market power effect and a negative externality due to the potential efficiency gains generated by the merger. The first effect arises as post-merger there is one less firm in the market and, *ceteris paribus*, pricing will be less aggressive leading to higher prices and profits ("price umbrella"). In both standard Industrial Organization models of imperfect competition – Cournot and Bertrand with differentiated products – market output declines and prices rise absent efficiency gains (e.g. Salant et al., 1983; Deneckere and Davidson, 1985; Farrell and Shapiro, 1990). Rival firms gain, as they do not bear the quantity reduction of insiders and nevertheless benefit from the higher prices.¹⁰ The second effect, higher efficiency, leads to lower prices, benefits insiders and consumers, while rival firms lose from fiercer competition. It is likely that in most mergers both effects are simultaneously present; we therefore look at the net effects.¹¹ Our first maintained assumption is as follows.

Assumption 1. Anticompetitive mergers generate a positive externality on rivals, i.e. an increase in rivals' profits identify anticompetitive, i.e. consumer welfare decreasing, rents.

Our identifying assumption, i.e. the relation between the increase in rivals' profits and the decrease in consumer surplus (CS), is theoretically satisfied by many – but not all – oligopolistic environments. Our framework focuses on the Industrial Organization approach of unilateral effects in horizontal mergers in a static setting. There are situations in which the identification of changes in consumer surplus through changes in competitors' profits may break down. For instance, in a dynamic context of sequential mergers (e.g. Nocke and Whinston, 2010), our identification would work only under certain conditions. In particular, whether our assumption holds will crucially depend on the nature of the sequence of mergers.¹² Second, the correspondence might also be lost in non-horizontal mergers, e.g. in a vertical merger consumers may be hurt as well as rivals if the merger forecloses competitors. Finally, the correspondence might be lost in the presence of strong agency problems, when mergers are undertaken for managerial reasons which contrast with profit maximization (see Gugler et al., 2003).

Therefore, we expect our approach to be more appropriate for horizontal (rather than vertical or conglomerate) mergers, for mergers which do not come in an industry-specific wave and where the signaling of future industry-wide efficiency is less important, and for profitable (rather than unprofitable) mergers. We do not think that non-horizontal mergers are problematic for the present study, as most of the mergers in our sample have predominantly horizontal effects and would now fall under the "Horizontal Merger Guidelines". However, we add in all regressions a dummy that takes on the value of one in all those mergers, for which the Commission identified "vertical", "foreclosure", or "conglomerate" concerns. Moreover, to more directly address this issue, we run a robustness check, where we exclude all mergers that

¹⁰ The papers by Duso et al. (2007a) and Gugler and Siebert (2007) provide a formal analysis of this point in a Cournot framework. They also prove that this theoretical identification also holds in Bertrand models of price competition and product differentiation.

¹¹ In a Cournot setting and absent any efficiency gains, the merger is always profitable for the rivals, yet it is only profitable for the merging firms if they reach a large share of the market. This result is known as the merger paradox (Salant et al., 1983). However, if the merger achieves some cost savings for the merging parties, then also smaller mergers might become profitable (Farrell and Shapiro, 1990).

¹² Nocke and Whinston (2010) show that if a merger is CS-decreasing in isolation it remains CS-decreasing if another merger takes place that is CS-non-increasing in isolation. However, there might be situations where a CS-decreasing merger becomes CS-increasing conditional on a previous CS-non-decreasing merger occurring.

were not purely horizontal according to the Commission's analysis. We next turn to measuring announcement and decision effects of mergers.

4.2. Measuring announcement and decision effects

The second step of our approach consists of choosing an empirical measure for the profit effects of a merger and the merger control decision. Following a long tradition in merger analysis starting with [Eckbo \(1983\)](#) and [Stillman \(1983\)](#), we use stock market reactions to the announcement of a merger and the merger decision to evaluate the impact of such events on merging firms' and competitors' profits.¹³ Although this approach to evaluate the competitive effect of a merger has the clear advantages that we discussed above it might be problematic. Indeed, the abnormal returns measured around the merger announcement potentially entail four major components: (i) The merger's competitive effect (what we ought to measure), (ii) the effect of a shock that triggers the merger (the merger wave/future acquisition probability or in-play effect), (iii) the information about the allocation of the role in one particular merger (e.g. the out-of-play effect), and (iv) the market expectations about the outcome of the antitrust procedure. Our second maintained hypothesis is as follows.

Assumption 2. After correcting for the market expectations about the outcome of the antitrust inquiry, CAARs around the merger-specific first rumors measure the merger's competitive effect.

This is clearly our most crucial assumption and it needs further discussion. First, if markets are semi-strong efficient, they should account for the future antitrust decision when reacting to a merger announcement (e.g. [Eckbo, 1992](#)). One of the innovations of this paper is to develop a strategy to account for these expectations.¹⁴ In Appendix B, we discuss our methodology to correct CAARs for the expectations about the Commission's decision. In short, we assume that the market builds expectations on the possible antitrust decision based on the public information about the merger and the Commission's records available in the market around the merger announcement. We quantify these expectations by estimating the probability of a particular decision as a function of the observable merger characteristics. We then correct our CAARs accordingly. The expectation-correction for the announcement CAARs make them a cleaner measure of the merger effect. The expectation-correction for the decision CAARs make them a clearer measure of the surprise entailed in the Commission's decision and, hence, of its competitive effect.

Second, we use the merger-specific first rumors in the business press as our measure for the merger announcement, since the surprise element to the stock market is likely to be largest around these dates and thus the merger's effects are likely to be best measured.¹⁵ This procedure can be regarded as standard in the event study literature. For instance, [Banerjee and Eckard \(1998\)](#) suggest using the first rumors about the merger instead of official announcement dates in order to reduce the likelihood that the merger is already anticipated and thus that abnormal returns are biased towards zero. However, as pointed out by [Fridolfsson and Stennek \(2009\)](#), this approach might only be useful if there were no previous rumors of a possible merger in the industry when the allocation of the roles (acquirer, target, rival) was still uncertain.¹⁶ It may also be argued that rumors are more likely to intermingle effects, since they are closer in time to any market shocks that might have triggered the merger. Official announcement dates occur after rumors and are less likely to capture market shocks. However, if the allocation of role around the first rumors was uncertain, they might contain the additional effect coming from the resolution of this uncertainty (out-of-play effect). In any case, as a robustness check, we re-estimate our main equations using official announcement dates instead of dates of first rumors.

Third, mergers might not be exogenous events but they might rather be triggered by market shocks, e.g. shocks in demand or costs (e.g. [Mitchell and Mulherin, 1996](#); [Jovanovic and Rousseau, 2002](#)). If these market shocks are priced in rather than the competitive effects of the merger, we may mis-measure anti—as well as pro-competitive rents. More in general, stock prices might also impound information effects. Early research (e.g. [Eckbo, 1983](#)) treated information effects vaguely simply positing that mergers signal positive information about an industry's value, and/or potential synergies between rivals and subsequent bidders. [Kim and Singal \(1993\)](#) note that such an effect has largely been interpreted as signals that 'rival firms are now more likely to be takeover targets'. Accordingly, more recent papers (e.g. [Song and Walking, 2000](#)) concentrated on how mergers can convey whether rivals are more or less likely to be targets in the future. Moreover, such information effects will be moderated by where on the wave the event takes place ([Akdogu et al., 2005](#)).¹⁷ In sum, an endogenous increase in future acquisition probabilities might influence our measures of the

¹³ In Appendix 1 we shortly review this standard methodology. A discussion of the literature using event studies in merger analysis can be found by [Duso et al. \(2007b\)](#).

¹⁴ Our approach is also in line with existing studies in the finance and corporate finance literature, e.g. [Malatesta and Thompson \(1985\)](#) and [Acharya \(1993\)](#), which propose a similar methodology to deal with the issue of separating the economic effects from anticipation effects.

¹⁵ When we say merger-specific rumor we mean the first article in the press where both target and acquirer were mentioned. A typical example is the following. "Allied Signals Inc., the diversified manufacturer, and Honeywell Inc., the maker of electronic controls, are in merger discussions, people close to the companies said yesterday." *The New York Times*, 06/05/1999.

¹⁶ Quoting [Fridolfsson and Stennek \(2009\)](#): "The out-of-play effect crucially hinges on the assumption that the market anticipates a merger but is uncertain about the allocation of the roles of acquirer, target and outsider."

¹⁷ Because of the increased merger activity levels associated with the pre-crest period of a merger wave, mergers occurring in this time-lap entail a higher probability of future acquisition for rivals (i.e. a larger information effect) than do mergers occurring in the post-crest period. Indeed, [Song and Walking \(2000\)](#) focus on merger announcements in the pre-crest period as involving the greatest information effect.

rivals' rents generated by the merger. Moreover, this information effect should increase at the beginning of a merger wave.¹⁸

We propose several robustness checks for each of these criticisms. To control for the effect of an industry-wide shock, we first partition the sample into two time periods: 1990–1995 and 1996–2002, during which a merger wave took place (see Gugler et al., 2006). One may be concerned that stock market reactions during this period were possibly unrelated to antitrust issues and mostly driven by economy-wide market shocks, such as the introduction of information technology that led to the dot-com stock market bubble in the late 1990s. Hence, we look at whether our results are consistent in this smaller, and potentially more problematic, subsample. If this is the case, then we might be less concerned that economy-wide merger waves strongly affect our findings.

Second, we look at industry-specific rather than economy-wide shocks conditioning on future merger activity. In particular, we partition our sample between those industries (“inactive industries”) that display below median merger activity growth in the 2 years following a particular merger and those industries (“active industries”), which display above median merger activity growth in the 2 years following a merger.¹⁹ Our Assumption 2 is more likely to hold in the inactive industries because endogenous increases in future acquisition probabilities should be less relevant.

Third, we discriminate between mergers on the basis of the time span elapsed between first rumors and the starting of the EC reviewing process (notification). Mergers differ according to the “speed” with which they are completed, and it may be argued that the time span between events matters for the assessment of a merger's competitive effects. For example, CAARs for mergers that take a long time to be consummated after the first rumors may be contaminated by other events/shocks like uncertainty over the feasibility of the merger itself or, as we discussed above, a shock triggering the mergers. We expect Assumption 2 to be more likely to hold for mergers that were speedily notified to the Commission, as stock markets may be more efficient at pricing in news when events are not too distant in time.²⁰

We now turn to the measurement of the effect of the Commission's decision. We formulate the following:

Assumption 3. After correcting for the market expectations about the outcome of the antitrust inquiry, CAARs around the Commission's decision measure the profitability effects of this decision.

First, we take the view that the Commission's final decision, conditional on the information already available around the merger announcement, entails a surprise element. As shortly discussed in Section 1, several arguments and anecdotal evidence justify this approach. There should be some surprise element in the decision process of the Commission, otherwise the market would not significantly react to such news, which it however does. This surprise element can come from surprises in the decision-making process itself, or errors in the merger control procedure (Duso et al., 2007a). Moreover, the fact that some announced mergers were later blocked by the Commission is indirect evidence that the decision process is not completely determined otherwise managers would probably not have announced these mergers in the first place.

Second, we focus on the direct effect of merger policy, i.e. the effect of a particular decision on the market and the firms involved in that decision either as merging parties or as rivals. As pointed out by Sørgard (2009), an optimal merger policy also entails deterrence, i.e. the effect a decision has on firms' future merger behavior. Indeed, Seldeslachts et al. (2009), by using a panel of antitrust jurisdictions over the period 1992–2003, find prohibitions to deter future merger activity, while remedies do not.

Our correction for market expectations should at least partially control for this issue, because, by conditioning on the available information around the merger announcement, we try to insulate the pure surprise element for any specific decision. Yet, we also suggest using the history of past Commission decisions as a robustness test. Industries may differ in how the Commission handles them in merger control. The Commission may define problematic industries, because concentration is already high, e.g. telecommunications, or industries of “national interest”, e.g. energy. Thus, the Commission's past decisions may convey important information on how this industry is treated or, put another way, the market can learn to better predict the Commission's decisions in these industries. Also, the Commission may learn how to implement effective remedies in specific industries. Thus, we define “remedy-intensive” and “remedy-un-intensive” industries in the robustness section, and test for differential effectiveness of remedies.²¹ In remedy-un-intensive industries, a decision to impose a remedy might entail a stronger signal about the Commission's future behavior in that particular industry. This might make our inference potentially less accurate as in this case the effect measured around the decisions might also entail indirect effects.

¹⁸ Clougherty and Duso (2009), by using the same dataset as in this paper, observe that rival CAARs do not seem to be influenced by the merger wave, and therefore positive rival CAARs do not appear to be a function of a higher future acquisition probability. Similarly, Simpson (2001) uses an event study to analyze a merger among US department stores. He finds positive abnormal returns to merging firms and their rivals, consistent with an increased concentration due to this merger. He shows that this pattern of abnormal returns seems to be better explained by the market power hypothesis rather than by the increased acquisition probability hypothesis.

¹⁹ To define these subsamples, we use the whole population of notified mergers in the time period between 1990 and 2002 (more than 3500) and define the industry according to the NACE codes used in the Commission's decision.

²⁰ We measure the “speediness” of the merger by the number of days between the first rumors and the official notification of the merger, and re-estimate our main results for rival firms for the subsamples of “speedy” vs. “slow” mergers. “Speedy” (“slow”) mergers are mergers for which the number of days between first rumors and notification is less (more) than the median number of days (55 days).

²¹ Also in this case, we use the entire population of mergers notified to the EU Commission between 1990 and 2002 to make this classification.

Finally, we believe that the market's response to news can be appropriately measured because the timing of the decision is tightly regulated, as we discussed in Section 3. However, not all decisions are given before the official deadline. Hence, one might argue that the timing of the Commission's decisions might itself be used by the market as a signaling device. For instance, a delay of the decision might signal that the Commission will be tougher than expected, while an earlier decision might come as a larger surprise to the market. Looking at the preliminary statistics, the average number of working days needed to come to a phase 1 decision after the merger notification is 27, which is quite close to the official deadline of 25 days. Similarly, for phase 2 decisions the average time elapsed after the opening of the in-depth investigation phase is 89 working days, which is quite close to the official 90 days fixed by the merger regulation.²² We therefore define "early" and "late" decisions. The former are cases where the Commission made its decision within 5 (25) days before the deadline in phase 1 (phase 2), while the latter are cases where the decisions come within 5 (10) days after the deadline in phase 1 (phase 2). As a robustness check, we run our regressions on the subsample of cases for which the decision did not come either too early or too late. For these cases, we expect the informative power of the expectation-corrected decision's CAARs to be the highest and hence our Assumption 3 to be more likely to hold.

4.3. Effectiveness assessment

Ideally, an effective merger control policy should be able to maintain the benefits to consumers generated by increased efficiency and, at the same time, reduce the market power effects of the merger.²³ This is particularly relevant for remedies which are supposed to cleanly separate these two effects. We therefore make the following simplifying assumption.

Assumption 4. The market power effects generated by a merger (Π^{MP}) can be partially separated from its efficiency effects ($\Pi^{efficiencies}$).

This assumption makes the analysis easier, yet we do not think it to be particularly restrictive. It is only needed in the case of remedies, which are the sole instruments trying to separate these two effects. Moreover, even in this case, we only need the reduction of the market power effect due to the remedy to be larger than the potential reduction in efficiencies, which might also follow from the remedy. Since the ability to separate these two effects is likely to increase with the experience of the antitrust authority, we expect this assumption to more likely hold in remedy-intensive industries. Hence, the robustness check proposed above will also serve as a robustness check for this issue.

The market power effect of a merger implies positive profits for both merging and rival firms, while the efficiency effect of a merger implies positive profits for the merging but negative profits for rival firms (Eckbo, 1983). Thus, if the action of the antitrust authority is effective, the decision-day abnormal returns of both merging and rival firms (Π_{ij}^{D*}) should be negative, since an effective decision wipes out the market power profits for both types of firms (Eckbo and Wier, 1985). More importantly, however, they should be systematically *negatively* related to announcement period abnormal returns. The larger the market power effect of the merger and, thus, the larger the announcement period abnormal returns (Π_{ij}^{A*}) for both types of firms, the more rent reversion there should be if the antitrust action is effective. Our methodology does not simply rely on the sign of the decision CAARs, but rather on the effective rent reversion as captured by the relation between announcement and decision CAARs.

We therefore propose assessing the "degree of effectiveness" of an antitrust action by running the following basic regression separately for merging firms and rivals:

$$\Pi_{ij}^{D*} = a_{idj} + b_{idj} \Pi_{ij}^{A*} + g_i X_j + \eta_{ij} \quad (1)$$

where the subscript i denotes either merging (M) or rival (R) firms, and the subscript j denotes the merger, which is our unit of observation. The subscript d represents the final Commission's decision (C =clearance; O =other remedies²⁴; S =structural remedies; and B =blockings). Thus, we estimate different intercepts as well as slope coefficients for the four types of decision. The b -coefficients measure the degree of rent reversion due to the specific EU Commission's decision. The variables contained in X are exogenous controls such as year and industry dummies and other merger-specific characteristics. In the following, based on our maintained Assumptions 1–4, we will discuss our hypotheses on the sign and size of the intercepts and slopes, which are then shown in Table 1. Appendix C presents a graphical representation of our framework.

Blockings: the most extreme action taken by the Commission, i.e. to block the merger, dissipates all rents, i.e. both the market power and the efficiency rents. Therefore, the null hypothesis $b_{iB} = -1$ should not be rejected for both rivals ($i=R$)

²² In particular 89% of the phase 1 decisions come in the range between 5 days before and 5 days after the official deadline of 25 days after notification, while 85% of the phase 2 decisions come in the range between 15 days before and 10 days after the official 90 working days after the opening of the in-depth investigation.

²³ This assumption is standard in merger models such as Farrell and Shapiro (1990), where the efficiency effects come from a marginal costs reduction achieved by the merging firms, while the market power effects come from the strategic reaction following the change in market structures determined by the merger.

²⁴ These are remedies that are not divestitures and which are mentioned in the Commission Notice on remedies (2001) <http://eurex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2001:068:0003:0011:EN:PDF>. They are mainly behavioral commitments, e.g. terminating existing exclusive agreements, granting access to a necessary infrastructure, or licensing agreements.

Table 1
Effective merger control.

	Predictions	
	Rivals ($i=R$)	Merging firms ($i=M$)
Blocking ($d=B$)	$a_{RB}=0, b_{RB}=-1$	$a_{MB}=0, b_{MB}=-1$
Remedies ($d=O, S, R$)	$a_{RO}<0, a_{RS}<0, a_{RR}<0$ $b_{RO}<0, b_{RS}<0, b_{RR}<0$	$a_{MO}=0, a_{MS}=0, a_{MR}=0$ $b_{MO}<0, b_{MS}<0, b_{MR}<0$
Clearance ($d=C$)	$a_{RC}=0, b_{RC}=0$	$a_{MC}=0, b_{MC}=0$

Note: a_{id} denotes the intercepts and b_{id} the slope coefficients ($i=M, R$ and $d=C, O, B$). First subscript: M for merging firms and R for rivals. Second subscripts: B for blocking; O for other remedies; S for structural remedies; C for outright clearance. In some specifications, we do not differentiate between structural and other remedies due to the lack of observations. Hence, we use the subscript R for remedies in these cases.

and merging firms ($i=M$): all rents generated by the merger are reversed by the final decision. Moreover, the regression line should pass through the origin: if there are no net rents generated by the merger, no rents are taken away by the decision, thus $a_{iB}=0$.

The failing of Assumptions 1–4 should not affect these predictions, since prohibitions should revert any kind of rents generated by the merger, simply because they bring back the pre-merger competitive situation. Hence, the nature of the rents (Assumption 1) and their composition (Assumption 4) should not matter, *ceteris paribus*. The failing of Assumptions 2 might instead bias our coefficient estimates. For instance, if our CAARs measured around the first rumor also capture the industry shock triggering the merger, then the b_{iB} coefficients might be smaller than one in absolute value. In fact, not all of the rents measured around the merger announcement can in this case be referred to the specific merger and, hence, reversed. If Assumption 3 fails to hold, the decision to block the merger might also entail signaling effects on the companies' market values not related to the specific deal. For example, the blocking decision could constitute a negative signal on the future possibilities to merge in the industry under scrutiny and thus depress share prices over and above the rents generated at the announcement. In this case, we would expect a negative coefficient a_{iB} and/or a coefficient b_{iB} smaller than -1 .

Clearance: under our maintained assumptions, if the merger is cleared without commitments, we do not expect decision effects that are systematically related to announcement returns, thus $a_{iC}, b_{iC}=0$ for merging firms and rivals. This does not need to be the case if Assumptions 2 or 3 fail. In this case, in fact, the CAARs might also signal other information. In particular, the reaction around the decision date might convey good news to the market about future mergers' feasibility. In this case, we might then expect a positive slope for the rivals (b_{RC}) if the clearing of the merger signals a green light from the Commission to mergers in that particular industry. This is even more likely if the Commission makes type II errors and unconditionally clears anticompetitive mergers.

Remedies: the situation is more complex in the case of remedies (both structural and other remedies). Only market power rents measured around the merger announcement should be entirely dissipated by the antitrust decision if it is effective. Hence, each remedial action will entail a negative decision effect for merging firms and rivals. However, this effect will be differently captured in our regression for merging firms and rivals.

For rivals, we expect a negative intercept ($a_{RO}<0, a_{RS}<0$) as well as a negative slope ($b_{RO}<0, b_{RS}<0$). The former captures the shift due to the elimination of the market power rents, while the latter indicates that rent reversion should be larger, the larger the size of the market power rents generated by the merger. For the merging firms, since both market power and efficiency effects are positive, we only expect a negative slope ($b_{MO}<0, b_{MS}<0$), while we expect a zero intercept ($a_{MO}=0, a_{MS}=0$).

Only in the case of remedies does Assumption 4 play an important role, as they are the only antitrust instruments which aim to separate market power from efficiency rents. As already mentioned, this separability does not need to be complete for our methodology to work. With decreasing separability, however, we would expect both the intercept and the slope in the regression for the rivals ($a_{RS}, a_{RO}, b_{RS}, b_{RO}$) to be biased towards zero. Hence, whether we should interpret lack of significance in the coefficient estimates for remedies as a lack of effectiveness will ultimately rest on the interpretation of the source of separability. In particular, it will rest on the question of whether the two kinds of rents are indeed theoretically not separable – because the nature of a particular implication of the merger is such that both kinds of effects simultaneously appear – or whether the authority is not able to find a remedy apt to reach this separability.²⁵

4.4. Further considerations

Phase 1 vs. phase 2: mergers that are cleared with or without commitments in phase 1 and mergers that go into phase 2 might be quite different. For example, the ex-post evaluation study conducted by DG Comp (2005) finds that remedies are

²⁵ For example, the closing of a branch of a bank due to a merger, might simultaneously have procompetitive effects (e.g. increase efficiencies by reducing duplication) and anticompetitive effects (e.g. reducing the number of local competitors). Eventually, no kind of action taken by the antitrust authority can separate these two effects.

mostly effective in phase 1. One of the reasons might be that these cases are simpler to fix, remedies in this investigation phase must be clear-cut and easy to implement, and the Commission has a stronger bargaining power vis-à-vis the merging firms through the credible threat of opening a costly phase 2 investigation. We shall test for differences in the remedies' effectiveness depending on whether the case was decided in phase 1 or phase 2.

Pro vs. anticompetitive mergers: the antitrust agency could wrongly intervene against pro-competitive mergers (type I errors) or approve anticompetitive mergers without remedying them (type II errors). We follow Duso et al. (2007a), and use rivals' merger announcement effects to measure anticompetitiveness. Under a consumer welfare standard, we can then define a merger to be anticompetitive (i.e. consumer's surplus reducing) if it increases competitors' profits, i.e. if $\Pi_{Rj}^A > 0$, and procompetitive if it reduces competitors' profits, i.e. if $\Pi_{Rj}^A < 0$. In the empirical section, we shall run regressions testing for the robustness of our results and discriminate between pro and anticompetitive mergers.²⁶ This will also allow us to analyze whether merger control average effectiveness is affected by the mistakes made by the Commission.

5. The data and the estimated abnormal returns

Our sample consists of 151 concentrations in the period 1990–2002 that have been analyzed by the European Commission. Our starting database was developed by Duso et al. (2007a). Our sample includes almost all phase 2 mergers scrutinized by the EC till the end of 2001, and a randomly drawn sample of phase 1 cases which run up to June 2002. Because of difficulties in identifying competitors or their stock, we end up with 71 phase 2 cases and 80 phase 1 cases for which we have complete information. We identify 544 different firms involved in the mergers either as merging parties or as rivals.

Merging firms and competitors are identified from the publicly available Commission's decisions.²⁷ This is one of the big advantages of our dataset, since we can rely on the Commission's analysis concerning the market definition (i.e. the relevant competitors).²⁸ Furthermore, the Commission's reports also provide in-depth information about the characteristics of the mergers and decisions, such as the kind of concentration (e.g. full vs. partial merger), the nature of the merger (pure horizontal vs. horizontal with conglomerate/vertical effects), the involved product and geographical markets, the kind of remedies imposed, the provenience of the involved firms, etc.

The merger announcement dates are collected from the financial press by using the Dow Jones Interactive database. This is a customizable business news and research product that integrates contents from newspapers, newswires, journals, research reports, and web sites. We look at the first rumors about the merger, i.e. the first time a discussion of the merger appears in the international press, but provide robustness checks using official announcement dates.²⁹ This has the advantage of reducing the noise in identifying the "right" event. Finally, we collect data on firms' stock prices and market values as well as market indexes, as defined by each firm's country-industry sector, by using Thomson Financial's Datastream.

Table 2 presents a short description of the relevant variables. The market value of the combined firms (rivals) is on average 45 (7.5) billion US dollars. On average, the Commission reports 7.6 rival firms, and we were able to find stock market information for 62.5% of them. The majority of the concentrations in our sample (57.1%) were full mergers, 24% joint ventures, 13.1% partial acquisitions, 11.3% tender offers, and only 6% consisted of asset acquisitions. In 41.1% of the cases the geographical market definition is the European Economic Area, in 35.1% it was defined to be national, in 21% it was worldwide, and in a few cases it was left open because the geographical market definition was not relevant for the decision.

Remedies have been imposed in 35.1% of the mergers (12.2% of phase 1 and 78% of phase 2 mergers), and 7.7% were blocked. Hence, in 42.8% of the cases in our sample the Commission took an action, i.e. intervened to modify or block the merger. Remedies are categorized as structural or behavioral using the information contained in the Commission's decision. In 23.5% of the cases the Commission ordered a divestiture, while in 11.8% it imposed other kinds of remedies.

Table 3 reports statistics on the cumulative average abnormal returns (CAARs) around various events using different event windows for merging firms and competitors. We consider a short window from 5 days before to 5 days after the relevant event, and a long window that goes back 50 days before the event to 5 days after.

The mergers in our sample were on average "profitable" since the CAARs for the merging firms around the announcement date are positive and statistically significant at the 5% level for all used windows. The size of the effects ranges from 1.05% in the short window to 1.8% in the long window. This result seems to be in line with

²⁶ Fee and Thomas (2004) and Shahrur (2005) propose using information on corporate customers to refine the Eckbo and Stillman methodology adopted by Duso et al. (2007a). This approach, which surely would substantially improve the identification of anticompetitive mergers, has the major drawback that, for many transactions, it is not possible to define customers that are quoted firms.

²⁷ The reports for each of the Commission's decisions can be downloaded from the Commission's webpage: <http://ec.europa.eu/competition/mergers/cases/>.

²⁸ In the existing literature, in fact, rivals are defined as all other firms in the industry, however, antitrust markets are generally fairly different from an industry. Therefore, we can significantly reduce the measurement error due to a too broad market definition, which would bias the competitors' abnormal return towards zero. This point was already put forward by Eckbo and Wier (1985).

²⁹ These are taken from the SDC database (Thomson Reuters).

Table 2
Preliminary statistics.

	Description	Obs	Mean	Min	Max
mvm	Market value of merging firms in million US\$	151	44,165	10,8	607,975
mvr	Market value of rivals (average) in million US\$	151	7492	3,6	227,604
ncomp	Number of competitors mentioned in the Commission report	151	7,59	1	34
ncomp_list	Percentage of mentioned competitors listed in the stock market	151	0,63	0	1
full	Full acquisition	151	0,57	0	1
partial	Partial acquisition	151	0,13	0	1
JV	Joint Venture	151	0,24	0	1
asset	Asset acquisition	151	0,06	0	1
tender	Tender offer	151	0,11	0	1
conglom	Conglomerate or vertical concerns have been identified	151	0,15	0	1
crossbord	Cross-border deal	151	0,69	0	1
us	One or both of the merging firms stem from the USA	151	0,33	0	1
bigeu	One or both of the merging firms stem from a major EU country (France, Germany, Italy, Spain, or the UK)	151	0,68	0	1
phase1	The merger was cleared in phase 1	151	0,54	0	1
phase2	The merger was cleared in phase 2	151	0,46	0	1
EU	The geographical market is the European Economic Area	151	0,41	0	1
World	The geographical market is worldwide	151	0,21	0	1
ACTION	An action (remedies or blocking) has been taken	151	0,43	0	1
BLOCK	The merger was prohibited	151	0,08	0	1
STRUCTURAL	The remedy consisted of a divestiture	151	0,23	0	1
OTHER	Other kinds of remedies	151	0,12	0	1

Table 3
Abnormal returns to merging firms and their rivals for various events, windows and decisions.

	Merging firms					Rivals				
	Nobs	Short run		Long run		Nobs	Short run		Long run	
		CAAR (5,5)	S.E.	CAAR (50,5)	S.E.		CAAR (5,5)	St.E.	CAAR (50,5)	St.E.
At announcement of the merger	151	0.010**	0.005	0.018**	0.010	151	-0.003	0.003	0.004	0.008
At phase 1 decision of the merger^a										
Cleared in phase 1	71	-0.002	0.007	0.003	0.010	71	-0.002	0.005	0.008	0.009
Cleared with remedies in phase 1	10	0.013	0.024	-0.007	0.033	10	-0.035*	0.020	0.032	0.066
Going to phase 2	70	-0.017***	0.006	-0.014***	0.008	70	-0.0001	0.005	-0.011	0.009
All	151	-0.008**	0.004	-0.005	0.006	151	-0.003	0.003	0.000	0.007
At phase 2 decision of the merger										
Cleared in phase 2	16	0.018	0.019	0.066***	0.037	16	0.001	0.010	0.001	0.022
Cleared with remedies in phase 2	41	0.003	0.012	-0.015	0.015	41	-0.004	0.008	-0.017	0.029
Blocked	13	0.008	0.009	0.008	0.049	13	0.025	0.025	-0.055	0.045
All	70	0.007	0.008	0.005	0.015	70	0.001	0.007	-0.019	0.348

* Significance at 10%.

** Significance at 5%.

*** Significance at 1%.

^a For the phase 1 decisions the long-run window is (25,5).

the literature.³⁰ The cumulative abnormal returns for the rivals around the announcement date are, instead, not statistically significantly different from zero and, on average, small in size. Looking at phase 1 decisions, we observe negative CAARs for the merging firms as well as for the rivals. The negative effect stems mainly from those cases where a phase 2 investigation was opened: the negative CAARs for the merging firms in that case are on average -1.7% in the short window and -1.4% in the long window. Similarly, rivals lose from the opening of a phase 2 investigation (in the long window up to -1.1%). For phase 2 decisions, almost all CAARs are statistically insignificant.

³⁰ See for instance Andrade et al. (2001). Depending on the event window, we estimate average abnormal returns for acquirers in the range between -0.54% and 0.12% (not statistically significantly different from zero) and for the targets in the range between 3.4% and 6.2% (statistically significantly greater than zero at the 1% level). These results are quite similar to those reported by Aktas et al. (2004) using a comparable sample of mergers.

Table 4
The probability of action.

	Coeff.	Std. err.
<i>us</i>	−1.314**	0.540
<i>bigeu</i>	−0.419	0.480
<i>conglom</i>	0.955*	0.568
<i>crossbord</i>	−0.476	0.459
<i>world</i>	−0.418	0.519
<i>eu</i>	− 0.844*	0.482
<i>full</i>	0.781*	0.421
<i>lmvm</i>	0.121	0.165
<i>lmvr</i>	0.183**	0.151
<i>d</i>	1.034**	0.508
<i>i</i>	0.673	0.637
<i>trend</i>	−0.949	0.611
<i>d95_02</i>	1.729*	0.921
<i>constant</i>	−2.452	1.688
Nobs		151
Pseudo- <i>R</i> ²		0.156
Correctly classified		69.48%
Log-likelihood		−88.80

Note: The dependent variable, ACTION, is equal to 1 if the merger was cleared with remedies or blocked. *us* is equal to 1 if one of the merging firms stems from the USA; *bigeu* is equal to 1 if one of the merging firms stems from a big EU country (Germany, France, UK, or Italy); *conglom* is equal to 1 if conglomerate or vertical effects are also present; *crossbord* is equal to 1 if the merger is a cross-border deal; *world* is equal to 1 if the EU Commission defines the relevant geographic market worldwide; *eu* is equal to 1 if relevant market is EU wide; *full* equal to 1 if the merger is a full merger; *lmvm* and *lmvr* are, respectively, the size of merging and rival firms measured by the logarithm of market values; *d* is equal to 1 if manufacturing sector; *i* is equal to 1 if communications sector; *trend* represents a time trend; *d95_02* equal to 1 if the merger was scrutinized during 1995–2002.

* Significance at 10%.

** Significance at 5%.

6. Results

6.1. The probability of an action

As discussed in Section 4 and in Appendix B, our first step is to estimate the probability that the Commission takes an action. The dependent variable is a dummy (ACTION) equal to 0 in the case of outright clearance and equal to 1 in the case of remedies or prohibitions. Table 4 reports the estimation results. The probability of an action is explained by several observable merger characteristics proxying for the merger's likely (anti) competitive effects, firms' lobbying, and/or protectionist tendencies of the antitrust agency: whether one or both of the merging firms stem from the USA (*us*), whether one or both of the merging firms stem from a major EU country (*bigeu*; France, Germany, Italy, Spain, or UK), whether conglomerate or vertical concerns have been identified (*conglom*), whether the merger is a cross border deal (*crossbord*), whether the EU Commission defines the relevant geographic market as worldwide (*world*), EU wide (*eu*) or national (reference group), whether the merger is a full merger (*full*; as opposed to partial acquisitions), the size of merging and rival firms measured by the logarithm of their market values (*lmvm* and *lmvr*, respectively), industry indicators (*d* for manufacturing and *i* for communications) and time variables (time trend and a dummy for the late years 1995–2002).³¹

The probability of an action is significantly lower if one or both of the merging firms stem from the USA³² or if markets are defined as EU wide. It significantly increases with the presence of conglomerate or vertical concerns,³³ the size of rival firms, if the firms operate in manufacturing, and during the last years of the sample (1995–2002). We correctly classify around 70% of the observations. From the reported estimates, we predict for each merger the probability of an action conditional on the public information available at the announcement date ($\Pr[\text{action}|I_A]$), and correct the estimated CAARs around the merger and decision announcements by the predicted probabilities according to the discussion presented in Appendix B. We run regression (1) using the probability corrected CAARs.

³¹ This dummy captures the years during which Mario Monti was the Competition Commissioner and several changes in merger control enforcement happened. These industry and time effects should also capture the learning process undergone by firms and investors about the Commission's decision. Indeed, it might be easier for the market to build expectations about a specific decision in late years and in industries where the Commission was more active.

³² Note that this result seems to contrast with the findings of Aktas et al. (2007), who claim that EU merger control is protectionist and favors European firms.

³³ A merger is defined to also have conglomerate or vertical (foreclosure) effects if the Commission stated so in its reports.

Table 5
Regression results for Eq. (1).

Dependent variable: probability corrected decision CAAR, Π^{D^*}	Rivals ($i=R$)			Merging firms ($i=M$)		
	Coeff.	Robust S.E.	Single tests H_0 (p-Values)	Coeff.	Robust S.E.	Single tests H_0 (p-Values)
CLEAR (a_{iC})	0.042	0.061	$H_0: a_{RC}=0$ 0.494	-0.020	0.093	$H_0: a_{MC}=0$ 0.832
OTHER REMEDIES (a_{iO})	0.013	0.037	$H_0: a_{RO} \leq 0$ 0.420	-0.095	0.056	$H_0: a_{MO} \leq 0$ 0.826
STRUCTURAL REMEDIES (a_{iS})	0.049	0.028	$H_0: a_{RS} \leq 0$ 0.233	-0.033	0.045	$H_0: a_{MS} \leq 0$ 0.626
BLOCK (a_{iB})	-0.061	0.041	$H_0: a_{RB}=0$ 0.410	-0.213	0.063	$H_0: a_{MB}=0$ 0.062
CLEAR * Π^{A^*} (b_{iC})	0.274	0.076	$H_0: b_{RC}=0$ 0.000	0.007	0.090	$H_0: b_{MC}=0$ 0.940
OTHER REMEDIES* Π^{A^*} (b_{iO})	-0.116	0.093	$H_0: b_{RO} \leq 0$ 0.893	-0.341	0.172	$H_0: b_{MO} \leq 0$ 0.975
STRUCTURAL REM.* Π^{A^*} (b_{iS})	-0.105	0.091	$H_0: b_{RS} \leq 0$ 0.874	-0.165	0.077	$H_0: b_{MS} \leq 0$ 0.983
BLOCK* Π^{A^*} (b_{iB})	-0.875	0.100	$H_0: b_{RB} = -1$ 0.211	-0.718	0.136	$H_0: b_{MB} = -1$ 0.040
Nobs	151			151		
R^2	0.539			0.325		

Note: We use the Huber–White sandwich estimator for robust standard errors. We control for industry effects, for conglomerate/foreclosure aspects, and for the proportion of rivals that we lost due to data limitation. CLEAR: the merger is cleared without remedies; OTHER REMEDIES: the merger is cleared with remedies other than divestitures (mainly behavioral remedies); STRUCTURAL REMEDIES: the merger is cleared with a divestiture; BLOCK the merger is blocked. We report the p -value for the tested hypotheses. Figures in bold represent estimates which are significantly different from zero at the 10% level at least.

6.2. Main results

Table 5 presents our main regression results. We choose the long window ($-50, +5$) to measure the merger's effect around its announcement, the short window ($-5, +5$) around phase 1 decisions, and again the long window ($-50, +5$) around phase 2 decisions. These strike us to be the best choices to account for information leakages.³⁴

In all specifications we control for time as well as industry effects (manufacturing and communications). This might capture aggregate or industry specific shocks, which might affect the decision CAARs. We also add a dummy equal to one for those cases where conglomerate and/or foreclosure aspects were identified by the Commission (i.e. not purely horizontal mergers). Finally, we control for the percentage of rivals identified by the Commission, for which we were able to get stock market information to control for possible measurement errors due to a potentially incomplete covering of the market.

Our first important findings are the significantly negative coefficients b_{iB} for outright blockings ($b_{RB} = -0.88$ for rivals and $b_{MB} = -0.72$ for merging firms), which are not statistically significantly different from minus one for rivals. Prohibitions seem to fully restore the pre-merger competitive situation and can be interpreted to be an effective merger control tool, according to our theoretical framework. The significantly negative intercept term for merging firms when the merger is blocked can be explained by additional costs (in addition to the lost market power and efficiency rents) of a blocked merger. These involve the direct costs of the lost merger proceedings and, probably more importantly, the indirect costs of the need to establish a new merger or business strategy. Hence, the fact that b_{MB} is not significantly smaller than minus one as well as the significantly negative constant for merging firms (a_{MB}) in the case of blockings might be explained by the CAARs entailing other signals such as the shock triggering the merger or the cost of the merger procedure itself.

Clearances do not have a positive effect on firms as witnessed by the zero intercepts, which is consistent with our hypotheses. However, the positive and significant estimate of the slope for rivals (b_{RC}) implies that their gains after an outright clearance increase with the size of their announcement gains, which we interpret as a possible measure of anticompetitiveness. The absence of an action by the antitrust authority conveys positive news to the market that future (possibly anticompetitive) mergers are feasible without provoking prolonged merger proceedings. This result might suggest that, on average, our Assumption 3 for clearances is too restrictive. We, however, favor an alternative interpretation, i.e. the market evaluating the cost of a type II error:

³⁴ Before the phase 1 decision, one should not expect much outflow of information as this investigation phase spans over a quite short time period, which is mostly used for administrative and procedural issues. Instead, information leakages might be an issue during phase 2, since this in-depth investigation lasts several months and attracts more public attention than phase 1. Moreover, the Commission might provide some information to the market by applying the so-called "market test", which asks competitors and customers to evaluate the proposed conditions. For further evidence supporting our choices also see Duso et al. (2007). Duso et al. (2010), using a subsample of the mergers used in this paper, show that the correlation between CAARs and ex-post-merger profitability measures based on accounting data is the highest for larger event windows. Moreover, Fridolfsson and Stennek (2009) give a theoretical rationale for preferring long windows. Finally, we run our main regressions using shorter windows and our qualitative results are not substantially altered.

Table 6
Phase 1 vs. phase 2.

Dependent variable: probability corrected decision CAAR, Π^{D*}	Rivals ($i=R$)			Merging firms ($i=M$)		
	Coeff.	Robust S.E.	Single tests H_0 (p-Values)	Coeff.	Robust S.E.	Single tests H_0 (p-Values)
Phase 1						
CLEAR (a_{iC})	0.075	0.031	$H_0: a_{RC}=0$ 0.018	-0.025	0.055	$H_0: a_{MC}=0$ 0.659
REMEDIES (a_{iR})	0.020	0.023	$H_0: a_{RR} \leq 0$ 0.305	-0.018	0.040	$H_0: a_{MR} \leq 0$ 0.602
CLEAR * Π^{A*} (b_{iC})	0.232	0.033	$H_0: b_{RC}=0$ 0.000	0.029	0.046	$H_0: b_{MC}=0$ 0.525
REMEDIES* Π^{A*} (b_{iR})	-0.190	0.054	$H_0: b_{RR} \leq 0$ 0.999	0.010	0.080	$H_0: b_{MR} \leq 0$ 0.450
Nobs	80			80		
R^2	0.650			0.249		
Phase 2						
CLEAR (a_{iC})	-0.035	0.246	$H_0: a_{RC}=0$ 0.889	0.272	0.319	$H_0: a_{MC}=0$ 0.397
OTHER REMEDIES (a_{iO})	-0.050	0.103	$H_0: a_{RO} \leq 0$ 0.588	0.069	0.159	$H_0: a_{MO} \leq 0$ 0.401
STRUCTURAL REMEDIES (a_{iS})	0.090	0.089	$H_0: a_{RS} \leq 0$ 0.353	0.207	0.132	$H_0: a_{MS} \leq 0$ 0.255
BLOCK (a_{iB})	-0.020	0.105	$H_0: a_{RB}=0$ 0.934	0.205	0.151	$H_0: a_{MB}=0$ 0.526
CLEAR * Π^{A*} (b_{iC})	0.199	0.462	$H_0: b_{RC}=0$ 0.668	0.158	0.708	$H_0: b_{MC}=0$ 0.825
OTHER REMEDIES* Π^{A*} (b_{iO})	0.042	0.503	$H_0: b_{RO} \leq 0$ 0.467	-0.823	0.545	$H_0: b_{MO} \leq 0$ 0.931
STRUCTURAL REM.* Π^{A*} (b_{iS})	0.531	0.177	$H_0: b_{RS} \leq 0$ 0.002	-0.217	0.149	$H_0: b_{MS} \leq 0$ 0.924
BLOCK* Π^{A*} (b_{iB})	-0.714	0.196	$H_0: b_{RB} = -1$ 0.151	-0.782	0.244	$H_0: b_{MB} = -1$ 0.377
Nobs	71			71		
R^2	0.570			0.474		

Note: We use the Huber–White sandwich estimator for robust standard errors. We control for industry effects, for conglomerate/foreclosure aspects, and for the proportion of rivals that we lost due to data limitation. CLEAR: the merger is cleared without remedies; OTHER REMEDIES: the merger is cleared with remedies other than divestitures (mainly behavioral remedies); STRUCTURAL REMEDIES: the merger is cleared with a divestiture; BLOCK the merger is blocked. We report the p-value for the tested hypotheses. Figures in bold represent estimates which are significantly different from zero at the 10% level at least.

the more anticompetitive the deal is (i.e. the larger the rivals’ rents at announcement), the more rivals profit from an outright clearance. Indeed, our next extension that looks at differences between anti and pro-competitive mergers (Table 7) is in line with this interpretation.

The coefficient estimates for remedies are only partly in line with the predictions for an effective merger control. In particular, the predicted negative shift for rivals is not observed, since the estimated intercepts (a_{iO} , a_{iS} for $i=M, R$) are not significantly different from zero. Yet, given the small coefficient estimates and the relatively large standard errors, we cannot reject the hypothesis of these coefficients being smaller than zero. The coefficient estimates for the slopes are negative for both rivals and merging firms (b_{iO} , b_{iS} for $i=M, R$), and for the latter they are significantly different from zero. For rivals, we cannot reject the hypothesis that they are negative, given the large standard errors. We interpret the negative estimates for the slopes as partial rent reversion and, hence, partial effectiveness of remedies.

To wrap up, the main results using the full sample are the following: (1) prohibitions achieve full rent reversion; (2) remedies achieve only partial rent reversion; (3) clearances increase rents for rivals and the larger the merger effect at announcement the more they do so. Our interpretation of these findings in terms of merger policy effectiveness is as follows: (1) prohibitions are an effective merger control tool; (2) remedies are only partially effective; and (3) some outright clearances might indeed be type II errors of the Commission.

6.3. Additional results

We next analyze phase 1 and phase 2 decisions (subsamples) separately in Table 6. For cases closed after a phase 1 investigation, we observe significant rent reversion in case of remedies for rival firms ($b_{RR} = -0.19$), even if the intercept (a_{RR}) is not significantly different from zero.³⁵ This again can be seen as consistent with remedies being, though only

³⁵ Due to the limited number of observations, we do not discriminate between structural and behavioral remedies.

Table 7
Pro- vs. anticompetitive mergers.

Dependent variable: probability corrected decision CAAR, Π^{D*}	Full sample					
	Rivals ($i=R$)			Merging firms ($i=M$)		
	Coeff.	Robust S.E.	Single tests H_0 (p-Values)	Coeff.	Robust S.E.	Single tests H_0 (p-Values)
CLEAR*ANTICOMP (a_{iC})	0.015	0.040	$H_0: a_{RC}=0$ 0.834	0.031	0.041	$H_0: a_{MC}=0$ 0.721
CLEAR*PROCOMP (a_{iC})	0.035	0.064	$H_0: a_{RC}=0$ 0.590	0.018	0.081	$H_0: a_{MC}=0$ 0.825
REMEDIES*ANTICOMP (a_{iR})	0.081	0.052	$H_0: a_{RR} \leq 0$ 0.150	-0.043	0.047	$H_0: a_{MR} \leq 0$ 0.685
REMEDIES*PROCOMP (a_{iR})	0.021	0.044	$H_0: a_{RR} \leq 0$ 0.387	0.011	0.044	$H_0: a_{MR} \leq 0$ 0.450
BLOCK (a_{iB})	-0.066	0.048	$H_0: a_{RB}=0$ 0.389	-0.257	0.058	$H_0: a_{MB}=0$ 0.010
CLEAR*ANTICOMP* $\Pi^{A*}(b_{iC})$	0.352	0.172	$H_0: b_{RC}=0$ 0.043	-0.226	0.123	$H_0: b_{MC}=0$ 0.067
CLEAR*PROCOMP* $\Pi^{A*}(b_{iC})$	0.193	0.127	$H_0: b_{RC}=0$ 0.129	0.020	0.105	$H_0: b_{MC}=0$ 0.847
REMEDIES*ANTICOMP* $\Pi^{A*}(b_{iR})^{**}$	-0.302	0.166	$H_0: b_{RR} \leq 0$ 0.964	-0.059	0.071	$H_0: b_{MR} \leq 0$ 0.797
REMEDIES*PROCOMP* $\Pi^{A*}(b_{iR})$	-0.089	0.122	$H_0: b_{RR} \leq 0$ 0.767	-0.695	0.119	$H_0: b_{MR} \leq 0$ 0.999
BLOCK* $\Pi^{A*}(b_{iB})$	-0.867	0.104	$H_0: b_{RB} = -1$ 0.201	-0.763	0.118	$H_0: b_{MB} = -1$ 0.047
Nobs	151			151		
R^2	0.497			0.469		

Note: We use the Huber–White sandwich estimator for robust standard errors. We control for industry effects, for conglomerate/foreclosure aspects, and for the proportion of rivals that we lost due to data limitation. CLEAR: the merger is cleared without remedies; OTHER REMEDIES: the merger is cleared with remedies other than divestitures (mainly behavioral remedies); STRUCTURAL REMEDIES: the merger is cleared with a divestiture; BLOCK the merger is blocked. We report the p -value for the tested hypotheses. Figures in bold represent estimates which are significantly different from zero at the 10% level at least. **ANTICOMP** is equal to one if rivals' announcement CAARs > 0 ($\Pi_{Rj}^{A*} > 0$); **PROCOMP** is equal to one if rivals' announcement CAARs < 0 ($\Pi_{Rj}^{A*} < 0$).

partially, effective in reverting market power rents when they are applied in phase 1, and it is in line with the findings by the Commission's in-house study (DG Comp, 2005). Similarly to the full sample, the intercept and slope coefficients for rivals (b_{RC}) in mergers that were out-rightly cleared are significantly positive. Again, one can interpret this finding as the cost of a type II error: some mergers with anticompetitive effects are cleared after a short investigation phase. This result is consistent with Duso et al. (2007a), who show that the probability of a type II error significantly increases in phase I.

The regressions run on the phase 2 subsample almost entirely replicate (and reinforce) the results observed in the full sample. Again, the consistency check for our procedure is successful, as the estimates for the blocking slopes (b_{iB}) are not significantly different from minus one. This is true not only for rivals but also for merging firms. Consistent with our predictions, the intercepts for blockings (a_{iB}) are not significantly different from zero for both merging firms and rivals. Furthermore, our hypotheses for out-rightly cleared mergers are also met for both merging firms and rivals, as the slopes (b_{iC}) as well as the intercepts (a_{iC}) are not significantly different from zero. We interpret this result as showing that it is less likely that a type II error is made after an in-depth investigation.

The major discrepancy is on the slopes for remedies. Now, the slope coefficient for structural remedies is estimated to be significantly positive for rivals (b_{RS}) and significantly negative for merging firms (b_{MS}). Our interpretation for this finding is that these possibly more complex remedies might merely result in rent transfers from merging firms to their rivals without correcting the anticompetitive nature of the merger. This interpretation seems intuitive: if the divested assets are purchased by existing competitors at below market prices (because there is time pressure and the Commission must agree to the identity of the buyer), rivals gain but effective competition might not be fully restored. This interpretation of our findings would imply that remedies in phase 2 are less of an effective merger control tool, on average.

The second extension consists of estimating different intercepts (a_{id}) and slopes (b_{id}) differentiating between anticompetitive (rival announcement CAARs = $\Pi_{Rj}^{A*} > 0$) vs. pro-competitive (rival announcement CAARs = $\Pi_{Rj}^{A*} < 0$) mergers (see Table 7).³⁶

Our main results carry over in that outright prohibitions exhibit full rent reversion (i.e. b_{iB} is not significantly different from -1) and remedies are only partially effective. In particular, remedies in anticompetitive mergers have a strong and significantly negative effect on rivals (b_{RR} for anticompetitive mergers), while, in the case of merging firms, a negative and

³⁶ Data limitations do not allow us to separately estimate the effect of prohibitions (BLOCK) for pro and anticompetitive mergers.

significant effect (b_{MR} for pro-competitive mergers) is observed when remedies are applied to pro-competitive mergers. This might point to costs for merging firms when a type I error occurs and the authority erroneously intervenes in a pro-competitive merger.

Finally, the clearance of an anticompetitive merger increases the rents earned by rivals (b_{RC} for anticompetitive mergers is positive), while not significantly influencing the merging firms: this kind of type II error (no remedies in anticompetitive mergers) seems to benefit the competitors without hurting the merging firms. Therefore, the positive slope for clearance, rather than to be understood as the failing of our Assumption 3, seems to be consistent with the market correctly evaluating the effects of the Commission's mistakes.

6.4. Robustness checks against the failing of our assumptions

In this section we discuss the robustness checks presented in Section 4.3 to account for the possible failure of our assumptions.

6.4.1. Purely horizontal mergers

Table 8 presents the estimates for our main regressions using the subsample of purely horizontal mergers (85% of the sample). These are mergers where the EU Commission did not identify any conglomerate or vertical effects. Our Assumption 1 should be more likely to hold for these mergers. For this subsample, most of our main findings carry over with comparable significance levels. The coefficients on blocked mergers are again not significantly different from minus one for rivals (b_{RB}), and smaller than minus one for merging firms (b_{MB}). Again, the effectiveness of remedies is only partially corroborated. Different from the full sample, the slope coefficient on other remedies (b_{MO}) for the merging firms is estimated to be significantly negative and that for rivals (b_{RO}) to be significantly positive. The interpretation we offer for this finding is that behavioral remedies in horizontal mergers would be a rent transfer from the merging firms to their competitors.

6.4.2. Official announcement dates

For our main estimations, the merger-specific first rumors are used as the merger announcement dates. Although this procedure can be seen as the standard in the literature, it may be argued that rumors are more likely to intermingle other effects, such as market shocks triggering the merger. This problem should be less severe at the official announcement dates at the cost that mergers might already be anticipated and measured effects are likely to be biased towards zero. We were able to obtain the announcement dates from the SDC database (Thomson Reuters) for a subsample of 120 out of our 151 mergers. A comparison of these two different sources of data reveals a fairly strong overlap for most of the events. However, there were also some events for which the date of the first rumor was substantially earlier than the

Table 8
Robustness check of Assumption 1: pure horizontal mergers.

Dependent variable: probability corrected decision CAAR, Π^{D*}	Pure horizontal					
	Rivals ($i=R$)			Merging firms ($i=M$)		
	Coeff.	Robust S.E.	Single tests H_0 (p-Values)	Coeff.	Robust S.E.	Single tests H_0 (p-Values)
CLEAR (a_{iC})	-0.027	0.073	$H_0: a_{RC}=0$ 0.715	0.023	0.087	$H_0: a_{MC}=0$ 0.790
OTHER REMEDIES (a_{iO})	-0.119	0.045	$H_0: a_{RO} \leq 0$ 0.941	-0.097	0.054	$H_0: a_{MO} \leq 0$ 0.854
STRUCTURAL REMEDIES (a_{iS})	-0.001	0.033	$H_0: a_{RS} \leq 0$ 0.506	0.031	0.042	$H_0: a_{MS} \leq 0$ 0.372
BLOCK (a_{iB})	-0.102	0.050	$H_0: a_{RB}=0$ 0.251	0.242	0.059	$H_0: a_{MB}=0$ 0.022
CLEAR * Π^{A*} (b_{iC})	0.235	0.095	$H_0: b_{RC}=0$ 0.015	-0.096	0.089	$H_0: b_{MC}=0$ 0.286
OTHER REMEDIES* Π^{A*} (b_{iO})	0.886	0.169	$H_0: b_{RO} \leq 0$ 0.000	-0.365	0.175	$H_0: b_{MO} \leq 0$ 0.980
STRUCTURAL REM.* Π^{A*} (b_{iS})	-0.077	0.106	$H_0: b_{RS} \leq 0$ 0.765	0.061	0.109	$H_0: b_{MS} \leq 0$ 0.288
BLOCK* Π^{A*} (b_{iB})	-0.865	0.134	$H_0: b_{RB} = -1$ 0.315	-1.325	0.136	$H_0: b_{MB} = -1$ 0.018
Nobs	129			129		
R ²	0.560			0.570		

Note: We use the Huber–White sandwich estimator for robust standard errors. We control for industry effects, for conglomerate/foreclosure aspects, and for the proportion of rivals that we lost due to data limitation. We report the p-value for the tested hypotheses. Figures in bold represent estimates which are significantly different from zero at the 10% level at least. **Pure horizontal mergers** are those for which the Commission identified only horizontal effects and no conglomerate or vertical effects.

Table 9
Robustness check of Assumption 2: using the official announcement dates.

Dependent variable: probability corrected decision CAAR, Π^{D^*}	Rivals			Merging firms		
	Coeff.	Robust S.E.	Single tests H_0 (p-Values)	Coeff.	Robust S.E.	Single tests H_0 (p-Values)
CLEAR (a_{iC})	0.200	0.114	$H_0: a_{RC}=0$ 0.082	0.007	0.118	$H_0: a_{MC}=0$ 0.703
OTHER REMEDIES (a_{iO})	-0.106	0.113	$H_0: a_{RO} \leq 0$ 0.826	-0.129	0.135	$H_0: a_{MO} \leq 0$ 0.564
STRUCTURAL REMEDIES (a_{iS})	0.155	0.122	$H_0: a_{RS} \leq 0$ 0.103	-0.052	0.094	$H_0: a_{MS} \leq 0$ 0.999
BLOCK (a_{iB})	-0.009	0.149	$H_0: a_{RB} \leq 0$ 0.523	-0.473	0.320	$H_0: a_{MB}=0$ 0.926
CLEAR * Π^{A^*} (b_{iC})	0.303	0.054	$H_0: b_{RC}=0$ 0.000	0.008	0.098	$H_0: b_{MC}=0$ 0.830
OTHER REMEDIES* Π^{A^*} (b_{iO})	0.054	0.086	$H_0: b_{RO} \leq 0$ 0.264	0.246	0.089	$H_0: b_{MO} \leq 0$ 0.004
STRUCTURAL REM.* Π^{A^*} (b_{iS})	-0.218	0.253	$H_0: b_{RS} \leq 0$ 0.805	-0.168	0.187	$H_0: b_{MS} \leq 0$ 0.414
BLOCK** Π^{A^*} (b_{iB})	-0.939	0.243	$H_0: b_{RB} = -1$ 0.803	-0.887	0.800	$H_0: b_{MB} = -1$ 0.256
Nobs	120			120		
R^2	0.38			0.36		

Note: We control for industry effects, for conglomerate/foreclosure aspects, and for the proportion of rivals that we lost due to data limitation. We report the p -value for the tested hypotheses. Figures in bold represent estimates which are significantly different from zero at the 10% level at least. The **official announcement** is defined according to the SDC database (Thomson Reuters). We use the Huber–White sandwich estimator for robust standard errors.

announcement dates in the SDC database. Hence, as a first robustness check for our Assumption 2, we run the basic regression using this alternative event for the merger announcement (see Table 9).

Results are very comparable to those obtained with our preferred definition of the merger announcement. We still cannot reject the hypothesis $b_{iB} = -1$ ($i=M, R$) for both merging and rival firms. The intercepts for structural and other remedies (a_{MS}, a_{MO}) are negative for merging firms, while only the latter (a_{RO}) is negative for rivals and the former (a_{RS}) is positive. In all these cases, we cannot reject our hypotheses of these intercepts being negative. Both slopes for structural remedies are negative for merging firms and rivals (b_{MS}, b_{RS}), while both slopes for other remedies are positive (b_{MO}, b_{RO}). These results are again only partially consistent with remedies being capable of reverting rents measured at the merger announcement. Also in this case, we observe positive and significant reactions (i.e. both constant a_{RC} and slope b_{RC}) for clearances for rivals.

6.4.3. Post-1996—the merger wave

Our sample period, 1990–2002, saw huge speculative stock price appreciations with a commensurate merger wave in the second-half of the 1990s. The following robustness check for Assumption 2 consists of controlling for this economy-wide merger wave. We split the sample into a pre-1996 period (1990–1995) and a post-1996 (1996–2002) period, for which we have shown the results in Table 10.

Our results are robust to merger wave arguments. We still cannot reject the hypothesis $b_{RB} = -1$, and the estimated slope for merging firms is just a bit smaller than in the full sample ($b_{MB} = -0.67$). Hence, the potential bias in our main findings seems to be quite limited. On remedy effectiveness, we obtain very similar results as in the full sample: remedies are only partially effective in reverting announcement rents. Moreover, the coefficient for structural remedies might again be interpreted to be consistent with a rent transfer from merging firms ($b_{MS} = -0.185$ and significant) to rivals, for which the slope coefficient is positive ($b_{RS} = 0.395$) and significant.

6.4.4. Future merger activity

We next re-estimate our main equation for the two subsamples “inactive” vs. “active” industries to control for industry-specific merger waves. This set of results should provide a robustness check for the failure of assumptions 1 and 2. Table 11 presents the results.

Our main findings for the two subsamples are qualitatively similar, yet some differences also emerge. The slopes for blocking (b_{iB}) are not significantly different from minus one in both subsamples, although the magnitudes of the point estimates are reduced particularly in the “inactive” subsample.³⁷ Remedies appear to be only partially effective, as the slopes for both remedy types, in both subsamples, are negative for merging firms (b_{MO}, b_{MS}) and, apart of behavioral

³⁷ Moreover, in the “inactive” subsample we also estimate a positive intercept for rivals in the case of prohibitions (a_{RB}). If outside the wave (“inactive” industries) mergers are on average more efficient (e.g. Gugler et al., 2003), this might be interpreted as the cost of a type I error: the Commission blocks a pro-competitive merger and, therefore, favors the rivals.

Table 10
Robustness check of Assumption 2: post-1996.

Dependent variable: probability corrected decision CAAR, Π^{D*}	Post-1996					
	Rivals ($i=R$)			Merging firms ($i=M$)		
	Coeff.	Robust S.E.	Single tests H_0 (p-Values)	Coeff.	Robust S.E.	Single tests H_0 (p-Values)
CLEAR (a_{iC})	0.022	0.066	$H_0: a_{RC}=0$ 0.743	0.072	0.081	$H_0: a_{MC}=0$ 0.378
OTHER REMEDIES (a_{iO})	-0.027	0.066	$H_0: a_{RO} \leq 0$ 0.625	-0.042	0.079	$H_0: a_{MO} \leq 0$ 0.661
STRUCTURAL REMEDIES (a_{iS})	0.031	0.045	$H_0: a_{RS} \leq 0$ 0.340	0.020	0.056	$H_0: a_{MS} \leq 0$ 0.413
BLOCK (a_{iB})	-0.066	0.069	$H_0: a_{RB} \leq 0$ 0.464	-0.481	0.079	$H_0: a_{MB}=0$ 0.000
CLEAR * Π^{A*} (b_{iC})	0.252	0.111	$H_0: b_{RC}=0$ 0.026	-0.008	0.106	$H_0: b_{MC}=0$ 0.942
OTHER REMEDIES* Π^{A*} (b_{iO})	-0.106	0.136	$H_0: b_{RO} \leq 0$ 0.781	-0.338	0.192	$H_0: b_{MO} \leq 0$ 0.959
STRUCTURAL REM.* Π^{A*} (b_{iS})	0.395	0.132	$H_0: b_{RS} \leq 0$ 0.002	-0.185	0.089	$H_0: b_{MS} \leq 0$ 0.980
BLOCK* Π^{A*} (b_{iB})	-0.843	0.178	$H_0: b_{RB} = -1$ 0.379	-0.687	0.152	$H_0: b_{MB} = -1$ 0.042
Nobs	104			104		
R^2	0.418			0.476		

Note: We use the Huber–White sandwich estimator for robust standard errors. We control for industry effects, for conglomerate/foreclosure aspects, and for the proportion of rivals that we lost due to data limitation. We report the p -value for the tested hypotheses. Figures in bold represent estimates which are significantly different from zero at the 10% level at least. The **post-1996** period includes the years 1996–2002, i.e. the years of the economy-wide merger wave.

remedies, also for rivals (b_{RO}). Again, clearances are greeted with a positive share price reaction in both subsamples for both rivals and merging firms (a_{iC}). In sum, while we cannot rule out the possibility that announced mergers endogenously increase future merger activity in particular industries (i.e. the “active” industries), the relation between decision and announcement CAARs does not appear to be affected.

6.4.5. Time between first rumors and notification

The speed with which mergers are completed differs across mergers, and the time spans between events might matter for the assessment of competitive effects. The larger the time span between the first rumor and the official notification, the more likely our CAARs can be contaminated by other sources of uncertainty about the merger and, therefore, the more likely it is that our Assumption 2 does not hold. We therefore differentiate between “slow” and “speedy” mergers and report the results for the two subsamples in Table 12.

As expected, results for “speedy” mergers are much more in line with our predictions. The coefficient on blockings for rivals is $b_{RB} = -1.03$ and not significantly different from minus one confirming full rent reversion after a merger is blocked. For merging firms, the slope on blockings b_{MB} is -2.22 , yet quite imprecisely estimated. In the “slow” mergers subsample the slope on blockings for rivals (b_{RB}) is negative but not significantly different from minus one. This may be attributable to the longer time span between first rumors and notification, and the implied measurement errors. The results on remedies are quite similar to those observed in the full sample, although there is more rent reversion in the subsample of “speedy” mergers for merging firms. This robustness check essentially shows that reducing measurement errors, i.e. making it more likely that our Assumption 2 holds, moves the empirical findings closer to the predictions of our framework.

6.4.6. Remedy intensive industries

The Commission’s past decisions are important for a number of reasons. First, besides intrinsic characteristics such as merger intensity or growth, industries may differ in how the antitrust authority treats them. Second, the Commission’s past decisions may convey important information to the market with respect to future decisions. Hence, the signal-to-noise ratios of our measured abnormal returns may vary across industries. Finally, the Commission may learn how to implement effective remedies in specific industries. To analyze these issues and offer a robustness check for Assumptions 3 and 4, we define remedy-intensive industries, where we expect our predictions to be more precisely met. Table 13 presents our findings.

Results are again very much in line with our previous conclusions. Both for merging firms and rivals, prohibitions reverse rents generated around the merger announcement. The remedies’ effectiveness is substantially increased in remedy-intensive industries: all four slope coefficients have a negative sign (b_{iO} , b_{iS}), three of them are significant, and the

Table 11
Robustness check of Assumptions 1 and 2: “active” vs. “inactive” Industries.

Dependent variable: probability corrected decision CAAR, Π^{D*}	Rivals ($i=R$)			Merging firms ($i=M$)		
	Coeff.	Robust S.E.	Single tests H_0 (p-Values)	Coeff.	Robust S.E.	Single tests H_0 (p-Values)
Active						
CLEAR (a_{iC})	0.109	0.074	$H_0: a_{RC}=0$ 0.146	0.076	0.127	$H_0: a_{MC}=0$ 0.554
OTHER REMEDIES (a_{iO})	-0.120	0.138	$H_0: a_{RO} \leq 0$ 0.805	0.025	0.161	$H_0: a_{MO} \leq 0$ 0.876
STRUCTURAL REMEDIES (a_{iS})	0.099	0.106	$H_0: a_{RS} \leq 0$ 0.178	0.043	0.175	$H_0: a_{MS} \leq 0$ 0.403
BLOCK (a_{iB})	0.113	0.101	$H_0: a_{RB} \leq 0$ 0.268	-0.079	0.319	$H_0: a_{MB} \leq 0$ 0.805
CLEAR * Π^{A*} (b_{iC})	0.201	0.103	$H_0: b_{RC}=0$ 0.057	-0.209	0.104	$H_0: b_{MC}=0$ 0.050
OTHER REMEDIES* Π^{A*} (b_{iO})	0.561	0.530	$H_0: b_{RO} \leq 0$ 0.147	-0.461	0.458	$H_0: b_{MO} \leq 0$ 0.841
STRUCTURAL REM.* Π^{A*} (b_{iS})	-0.069	0.270	$H_0: b_{RS} \leq 0$ 0.600	-0.190	0.363	$H_0: b_{MS} \leq 0$ 0.698
BLOCK* Π^{A*} (b_{iB})	-0.654	0.273	$H_0: b_{RB} = -1$ 0.210	-0.912	0.225	$H_0: b_{MB} = -1$ 0.696
Nobs	75			75		
R^2	0.333			0.433		
Inactive						
CLEAR (a_{iC})	0.322	0.116	$H_0: a_{RC}=0$ 0.008	0.197	0.125	$H_0: a_{MC}=0$ 0.200
OTHER REMEDIES (a_{iO})	0.176	0.140	$H_0: a_{RO} \leq 0$ 0.107	0.036	0.170	$H_0: a_{MO} \leq 0$ 0.107
STRUCTURAL REMEDIES (a_{iS})	0.279	0.132	$H_0: a_{RS} \leq 0$ 0.020	0.115	0.124	$H_0: a_{MS} \leq 0$ 0.177
BLOCK (a_{iB})	0.196	0.071	$H_0: a_{RB}=0$ 0.008	0.188	0.181	$H_0: a_{MB}=0$ 0.399
CLEAR * Π^{A*} (b_{iC})	0.008	0.217	$H_0: b_{RC}=0$ 0.970	0.347	0.122	$H_0: b_{MC}=0$ 0.230
OTHER REMEDIES* Π^{A*} (b_{iO})	0.273	0.280	$H_0: b_{RO} \leq 0$ 0.168	-0.155	0.154	$H_0: b_{MO} \leq 0$ 0.721
STRUCTURAL REM.* Π^{A*} (b_{iS})	-0.022	0.564	$H_0: b_{RS} \leq 0$ 0.515	-0.053	0.086	$H_0: b_{MS} \leq 0$ 0.901
BLOCK* Π^{A*} (b_{iB})	-0.651	0.209	$H_0: b_{RB} = -1$ 0.101	-0.686	0.388	$H_0: b_{MB} = -1$ 0.073
Nobs	76			76		
R^2	0.433			0.520		

Note: We use the Huber–White sandwich estimator for robust standard errors. We control for industry effects, for conglomerate/foreclosure aspects, and for the proportion of rivals that we lost due to data limitation. We report the p-value for the tested hypotheses. Figures in bold represent estimates which are significantly different from zero at the 10% level at least. The subsample of “inactive (active) industries” is defined by those cases for which the future merger growth rate by 2-digit NACE in the following 2 years is lower (larger) than 12% (the median values). We use the full population of more than 3500 notified EU mergers for this definition.

sizes in absolute terms of the coefficients are much larger than in the full sample. This indicates substantial rent reversion and, according to our interpretation, suggests that the Commission might have learned over time and in certain industries to implement more effective remedies.

6.4.7. Timely merger decisions

The timing of the Commission’s decision might convey additional information to the market, in which case our Assumption 3 might be hurt. We claim that the tightly regulated merger control process should reduce this problem. We drop all cases where the decision came too early or too late with respect to the regulated deadline and re-estimate our model on the subsample of mergers for which there was a “timely decision”.³⁸ Table 14 presents our results.

Our main results are reinforced. The slopes for blockings (b_{iB}) are not significantly different from minus one for rivals and merging firms. The slopes on remedies for merging firms (b_{MO} , b_{MS}) are (partially) significantly negative and larger in absolute value than in the full sample. The slope on structural remedies for rivals (b_{RS}) is negative and significant, while that for behavioral remedies (b_{RO}) is positive. Again, we interpret these findings as remedies being only partially effective.

³⁸ Excluding either only “early” or only “late” decisions leads to comparable results.

Table 12

Robustness check of Assumption 2: “speedy” vs. “slow” mergers.

Dependent variable: probability corrected decision CAAR, Π^{D*}	Rivals ($i=R$)			Merging firms ($i=M$)		
	Coeff.	Robust S.E.	Single tests H_0 (p-Values)	Coeff.	Robust S.E.	Single tests H_0 (p-Values)
Speedy						
CLEAR (a_{iC})	0.079	0.090	$H_0: a_{RC}=0$ 0.385	-0.021	0.103	$H_0: a_{MC}=0$ 0.839
OTHER REMEDIES (a_{iO})	0.039	0.133	$H_0: a_{RO} \leq 0$ 0.385	-0.060	0.139	$H_0: a_{MO} \leq 0$ 0.669
STRUCTURAL REMEDIES (a_{iS})	0.062	0.129	$H_0: a_{RS} \leq 0$ 0.402	-0.019	0.126	$H_0: a_{MS} \leq 0$ 0.561
BLOCK (a_{iB})	0.063	0.135	$H_0: a_{RB} \leq 0$ 0.645	-0.464	0.303	$H_0: a_{MB} \leq 0$ 0.131
CLEAR * Π^{A*} (b_{iC})	0.164	0.127	$H_0: b_{RC}=0$ 0.201	0.120	0.092	$H_0: b_{MC}=0$ 0.197
OTHER REMEDIES* Π^{A*} (b_{iO})	-0.281	0.224	$H_0: b_{RO} \leq 0$ 0.892	-0.623	0.303	$H_0: b_{MO} \leq 0$ 0.044
STRUCTURAL REM.* Π^{A*} (b_{iS})	0.188	0.761	$H_0: b_{RS} \leq 0$ 0.402	-0.179	0.067	$H_0: b_{MS} \leq 0$ 0.995
BLOCK* Π^{A*} (b_{iB})	-1.034	0.153	$H_0: b_{RB} = -1$ 0.827	-2.222	0.704	$H_0: b_{MB} = -1$ 0.221
Nobs	75			75		
R ²	0.510			0.570		
Slow						
CLEAR (a_{iC})	0.210	0.155	$H_0: a_{RC}=0$ 0.180	0.055	0.111	$H_0: a_{MC}=0$ 0.622
OTHER REMEDIES (a_{iO})	-0.190	0.125	$H_0: a_{RO} \leq 0$ 0.934	-0.159	0.147	$H_0: a_{MO} \leq 0$ 0.286
STRUCTURAL REMEDIES (a_{iS})	0.125	0.163	$H_0: a_{RS} \leq 0$ 0.223	0.027	0.135	$H_0: a_{MS} \leq 0$ 0.423
BLOCK (a_{iB})	0.134	0.177	$H_0: a_{RB}=0$ 0.452	0.029	0.210	$H_0: a_{MB}=0$ 0.891
CLEAR * Π^{A*} (b_{iC})	0.193	0.141	$H_0: b_{RC}=0$ 0.178	0.012	0.251	$H_0: b_{MC}=0$ 0.188
OTHER REMEDIES* Π^{A*} (b_{iO})	0.721	0.174	$H_0: b_{RO} \leq 0$ 0.000	-0.063	0.294	$H_0: b_{MO} \leq 0$ 0.585
STRUCTURAL REM.* Π^{A*} (b_{iS})	-0.117	0.430	$H_0: b_{RS} \leq 0$ 0.606	-0.234	0.325	$H_0: b_{MS} \leq 0$ 0.762
BLOCK* Π^{A*} (b_{iB})	-0.444	0.245	$H_0: b_{RB} = -1$ 0.027	-0.829	0.196	$H_0: b_{MB} = -1$ 0.388
Nobs	76			76		
R ²	0.416			0.481		

Note: We use the Huber–White/sandwich estimator for robust standard errors. We control for industry effects, for conglomerate/foreclosure aspects, and for the proportion of rivals that we lost due to data limitation. We report the p-value for the tested hypotheses. Figures in bold represent estimates which are significantly different from zero at the 10% level at least. “Speedy” (“slow”) mergers are cases for which the time distance between the first rumors about the merger and its notification is lower (larger) than 55 days (the median).

7. Conclusions

This paper is a first attempt to provide a framework to econometrically assess the effectiveness of merger control decisions. We do this by using a simple, intuitive, and novel approach based on stock market data: by looking at the relation between firms’ abnormal returns around the two major event dates, the merger and antitrust decision announcements, we obtain several testable hypotheses. We try to be cautious in isolating the true effects of the antitrust decisions through event studies. First, we account for information leakages prior to major events. Second, we adjust our profitability measures for the market expectations about the merger control procedure by using a probability correction method. Third, our dataset is as “clean” as possible in identifying major rivals of merging firms, hence the merger’s true competitive effect, as our sources for market definition are the decisions of the European Commission itself. Fourth, we propose several robustness checks based on different types of mergers, industries, and time periods to control for the possible failure of our framework’s crucial assumptions.

We find that outright prohibitions completely revert the rents generated around the merger announcement. Our interpretation of this finding is that they solve the anticompetitive concerns raised by the merger. This is also a consistency check for the reliability of our approach. Remedies, instead, do not seem to achieve this full rent reversion on average.

Table 13
Robustness check of Assumptions 3 and 4: remedy-intensive industries.

Dependent variable: probability corrected decision CAAR, Π^{D*}	Remedy-intensive industries					
	Rivals ($i=R$)			Merging firms ($i=M$)		
	Coeff.	Robust S.E.	Single tests H_0 (p-Values)	Coeff.	Robust S.E.	Single tests H_0 (p-Values)
Remedy-intensive industries						
CLEAR (a_{iC})	0.000	0.186	$H_0: a_{RC}=0$ 0.998	0.100	0.126	$H_0: a_{MC}=0$ 0.429
OTHER REMEDIES (a_{iO})	-0.046	0.065	$H_0: a_{RO} \leq 0$ 0.592	0.031	0.077	$H_0: a_{MO} \leq 0$ 0.415
STRUCTURAL REMEDIES (a_{iS})	0.011	0.051	$H_0: a_{RS} \leq 0$ 0.477	0.084	0.062	$H_0: a_{MS} \leq 0$ 0.250
BLOCK (a_{iB})	-0.097	0.075	$H_0: a_{RB} \leq 0$ 0.625	0.276	0.097	$H_0: a_{MB} \leq 0$ 0.059
CLEAR * Π^{A*} (b_{iC})	0.441	0.170	$H_0: b_{RC}=0$ 0.012	-0.148	0.143	$H_0: b_{MC}=0$ 0.304
OTHER REMEDIES* Π^{A*} (b_{iO})	-0.193	0.133	$H_0: b_{RO} \leq 0$ 0.924	-0.564	0.223	$H_0: b_{MO} \leq 0$ 0.993
STRUCTURAL REM.* Π^{A*} (b_{iS})	-0.533	0.162	$H_0: b_{RS} \leq 0$ 0.999	-0.193	0.087	$H_0: b_{MS} \leq 0$ 0.985
BLOCK* Π^{A*} (b_{iB})	-0.837	0.161	$H_0: b_{RB} = -1$ 0.315	-1.514	0.302	$H_0: b_{MB} = -1$ 0.094
Nobs	81			81		
R^2	0.590			0.587		

Note: We use the Huber–White sandwich estimator for robust standard errors. We control for industry effects, for conglomerate/foreclosure aspects, and for the proportion of rivals that we lost due to data limitation. We report the p-value for the tested hypotheses. Figures in bold represent estimates which are significantly different from zero at the 10% level at least. In **remedy-intensive industries**, defined at the two digit NACE code, the Commission imposed remedies including prohibitions in more than 10% of the mergers (i.e. the median). We use the full population of more than 3500 notified EU mergers for this definition.

Table 14
Robustness check of Assumption 3: timely decisions.

Dependent variable: probability corrected decision CAAR, Π^{D*}	Timely decisions					
	Rivals ($i=R$)			Merging firms ($i=M$)		
	Coeff	Robust S.E.	Single tests H_0 (p-Values)	Coeff	Robust S.E.	Single tests H_0 (p-Values)
CLEAR (a_{iC})	0.005	0.065	$H_0: a_{RC}=0$ 0.943	0.069	0.066	$H_0: a_{MC}=0$ 0.301
OTHER REMEDIES (a_{iO})	-0.263	0.176	$H_0: a_{RO} \leq 0$ 0.931	-0.021	0.082	$H_0: a_{MO} \leq 0$ 0.604
STRUCTURAL REMEDIES (a_{iS})	0.025	0.091	$H_0: a_{RS} \leq 0$ 0.394	0.031	0.084	$H_0: a_{MS} \leq 0$ 0.358
BLOCK (a_{iB})	-0.196	0.163	$H_0: a_{RB} \leq 0$ 0.625	-0.092	0.237	$H_0: a_{MB} \leq 0$ 0.703
CLEAR * Π^{A*} (b_{iC})	0.183	0.067	$H_0: b_{RC}=0$ 0.008	0.027	0.088	$H_0: b_{MC}=0$ 0.757
OTHER REMEDIES* Π^{A*} (b_{iO})	0.954	0.676	$H_0: b_{RO} \leq 0$ 0.081	-0.555	0.360	$H_0: b_{MO} \leq 0$ 0.937
STRUCTURAL REM.* Π^{A*} (b_{iS})	-0.577	0.286	$H_0: b_{RS} \leq 0$ 0.976	-0.110	0.089	$H_0: b_{MS} \leq 0$ 0.891
BLOCK* Π^{A*} (b_{iB})	-1.007	0.104	$H_0: b_{RB} = -1$ 0.945	-1.655	1.715	$H_0: b_{MB} = -1$ 0.094
Nobs	110			110		
R^2	0.4605			0.2273		

Note: We use the Huber–White sandwich estimator for robust standard errors. We control for industry effects, for conglomerate/foreclosure aspects, and for the proportion of rivals that we lost due to data limitation. We report the p-value for the tested hypotheses. Figures in bold represent estimates which are significantly different from zero at the 10% level at least. **“Timely decisions”** are decisions made according to the deadlines prescribed by the merger regulation. We exclude “early” and “late” decisions. The former are cases where the commission made its decision until 5 (25) days before the deadline in phase I (2), while the latter are cases where the decisions comes until 5 (10) days after the deadline in phase I (2).

We therefore interpret them as only partially effective. Yet, our methodology allows us to qualify this result in several directions. Remedies appear to be more effective in reverting rents generated at the merger announcement if they are ordered during the first investigation phase. This result, at first sight controversial, is in line with the empirical evidence provided by the ex-post evaluation study conducted by DG Comp (2005), which is based on a very different evaluation method. Remedies are mostly effective in phase 1 because these cases are simpler, remedies must be clear-cut and easily implementable, and the Commission has a stronger bargaining power with respect to the merging firms through the credible threat of opening a costly phase 2 investigation. Moreover, remedies seem to be more effective if correctly applied to anticompetitive mergers.

We find that rents following an outright clearance increase with the size of the merger announcement rents, but only for rivals. We interpret this result as a sign of the cost of possible type II errors, where anticompetitive deals are waved through. We provide three additional pieces of evidence confirming this interpretation. Finally we also offer insights about the evolution of European merger policy effectiveness over time. Apparently, the Commission has been able to learn over the years and from its past experience and has improved the effectiveness of its remedial action. Four main assumptions are the pillars on which our framework is funded. We run several robustness checks and show that our results are more in line with the predictions of our framework, when we focus on subsamples for which our maintained assumptions are more likely to hold. We also show that running our test on subsamples where some of our assumptions are less likely to hold, does not seem to have a significant impact on our main findings. We therefore believe we have provided quite robust results on the effectiveness of European merger control.

In recent years the EU Commission – in contrast to the US antitrust authorities – increasingly hesitates to block mergers, especially after the European Court of Justice overruled several of its blocking decisions. Our results imply that this may be problematic: remedies might be a good policy tool, when the anticompetitive concerns brought by the merger are not too serious. In complex mergers, which create serious worries about the post-merger industry's competitiveness, prohibitions might be the only tool capable of restoring effective competition.

Acknowledgments

We would like to thank Jo Seldeslachts and Joe Clougherty for many useful discussions and for providing us with some data and Stephen Davies, Espen Eckbo, Lars-Hendrik Röller, Dennis Mueller, Paul Heidhues, Jennifer Rontganger, Giancarlo Spagnolo, Konrad Stahl, seminar participants at the WZB, University of Vienna, University of Amsterdam, University of Mannheim, LMU University of Munich, City University London, UK Competition Commission, ESMT, and conference participants at the CEPR conferences in Paris (2005) and Brussels (2005), EEA 2006, EARIE 2007, and ASSET 2007 for helpful comments. We very much benefited from the detailed comments of three anonymous referees, the editor Gerard Pfann, and an associate editor. Cinzia Alcidi, Claudia Baldermann, and Constanze Quade provided excellent research assistance. Tomaso Duso gratefully acknowledges partial financial support from the Deutsche Forschungsgemeinschaft through SFB/TR 15. Klaus Gugler and Burcin Yurtoglu gratefully acknowledge support by the OeNB Jubilaeumsfonds and the Austrian FWF.

Appendix A. Event study methodology

Under the assumptions of efficient markets and rational expectations, the market model predicts that firm f 's stock return at day t ($R_{f,t}$) is proportional to a daily market return ($R_{m,t}$):

$$R_{f,t} = \alpha + \beta R_{m,t} + \varepsilon_{f,t}$$

We estimate the market model over 240 trading days, starting 50 days prior to the announcement day and using the Scholes and Williams (1977) method. Using the model's parameters α and β , we predict what firm f 's stock price would have been, had the event under consideration (merger announcement or antitrust decision) not occurred, i.e. the abnormal returns are

$$AR_{f,t} = R_{f,t} - \hat{R}_{f,t} = R_{f,t} - \hat{\alpha} - \hat{\beta} R_{m,t}$$

With efficient markets abnormal returns have zero mean and a variance equal to

$$\text{Var}(AR_{f,t}) = \sigma_{\varepsilon_{f,t}}^2 + \frac{1}{L} \left[1 + \frac{R_{m,t} - \bar{R}_m}{\sigma_m^2} \right]$$

where L is the estimation period length and \bar{R}_m and σ_m^2 are, respectively, the mean and variance of the market portfolio. We then calculate the cumulative abnormal return over an event window (τ_1, τ_2) :

$$CAR_{f,\tau_1,\tau_2} = \sum_{\tau=\tau_1}^{\tau=\tau_2} AR_{f,\tau}$$

To obtain the aggregate effects of the merger j on merging firms ($i=M$) and on rivals ($i=R$) around the events of interest, II_{ij}^e ($e=A, D$; announcement and decision), we take the weighted average of the cumulative abnormal returns of

all firms in each of the two groups, the weight being firm f 's market value:

$$\Pi_{ij}^e = \frac{\sum_{f=1}^{N_{ij}} CAR_f^e MV_f^e}{\sum_{f=1}^{N_{ij}} MV_f^e}, \quad i = M, R, \quad e = A, D$$

where N_{ij} is the number of firms in class i involved in merger j .

Appendix B. Accounting for market expectations

If markets are semi-strong efficient, they should account for the future antitrust decision when reacting to a merger announcement (e.g. Eckbo, 1992). We assume that the market builds expectations about the effect of the Commission's decision d (clearance or action, which includes blockings and any kind of remedies), given the *public* information available in the market around the merger announcement (I_A). When expectations are rational, the expected value of the Commission's decision can be written as

$$E[\Pi_{ij}^D | I_A] = \sum_d \Pi_{ij}^D \Pr[d_j | I_A], \quad d = \text{clear, action}$$

where $\Pr[d_j | I_A]$ is the probability assigned by the market to decision d given the information available around the merger's announcement.

The observed abnormal return for firms i around the announcement day (Π_{ij}^A) is then equal to the competitive effect of merger j for firms i (Π_{ij}^{A*}) minus the expected value of the effect of the Commission's decision. Assuming that any effective action (remedies or blockings) effectively wipes out all market power profits accruing from the merger, i.e. $\Pi_{ij}^{D^a} = -\Pi_{ij}^{A*}$, and a clearance does not have any profitability effect, i.e. $\Pi_{ij}^{D^c} = 0$, we can then write the following:

$$\begin{aligned} \Pi_{ij}^A &= \Pi_{ij}^{A*} + E[\Pi_{ij}^{D^*} | I_A] \\ &= \Pi_{ij}^{A*} + \Pi_{ij}^{D^c} \Pr[\text{clear}_j | I_A] + \Pi_{ij}^{D^a} \Pr[\text{action}_j | I_A] \\ &= \Pi_{ij}^{A*} (1 - \Pr[\text{action}_j | I_A]) \end{aligned}$$

Therefore, the competitive effect of merger j on firms i is

$$\Pi_{ij}^{A*} = \Pi_{ij}^A / (1 - \Pr[\text{action}_j | I_A]) \tag{A.1}$$

i.e. the measured announcement CAAR divided by the ex-ante probability that the merger will be cleared without conditions. The market can build a prior of this probability using available information about the merger and the Commission's records. This is what the econometrician can do by running a logit regression to assess the probability of clearance given the merger observables.

Similarly, at the time of the Commission's decision some new information hits the market. The first important date is the phase 1 decision. The phase 1 decision's effect (Π_{ij}^{P1}) is the difference between the antitrust decision's competitive effect on firm i ($\Pi_{ij}^{D^*}$) and the market expectation about it. Similarly, if anticompetitive concerns are substantial and the Commission decides to open a phase 2 investigation, the market updates its beliefs about remedies.³⁹ Therefore, the abnormal returns around the phase 1 decision (Π_{ij}^{P1}) for mergers that go into a phase 2 investigation should simply be the update of the market expectation about remedies, given the newer information set available at this point in time (I_{P1}). Summarizing, the phase 1 effect is the following:

$$\Pi_{ij}^{P1} = \begin{cases} \Pi_{ij}^{D^*} - E[\Pi_{ij}^{D^*} | I_A] = \Pi_{ij}^{D^*} (1 - \Pr[\text{action}_j | I_A]) & \text{if phase 1} \\ E[\Pi_{ij}^{D^*} | I_{P1}] - E[\Pi_{ij}^{D^*} | I_A] & \text{if phase 2} \end{cases}$$

The competitive effect of the Commission's decision for a case that does not go into phase 2 is thus

$$\Pi_{ij}^{D^*} = \frac{\Pi_{ij}^{P1}}{(1 - \Pr[\text{action}_j | I_A])} \tag{A.2}$$

Similarly for cases going into phase 2, around the phase 2 decision, the abnormal return (Π_{ij}^{P2}) should measure the difference between the competitive effect of a remedy in phase 2 and the expectation that the market built given the information available on the phase 1 decision $\Pi_{ij}^{P2} = \Pi_{ij}^{D^*} - E[\Pi_{ij}^{D^*} | I_{P1}] = \Pi_{ij}^{D^*} - \Pi_{ij}^{P1} - E[\Pi_{ij}^{D^*} | I_A]$, $i = M, R$. Hence, the competitive effect of the Commission's decision for cases that go into phase 2 is the sum of phase 1 and phase 2 effects weighted by the

³⁹ Indeed, when a case goes into phase 2, the probability of an antitrust intervention increases sharply. According to the European Commission's statistics, the incidence of remedies in phase 1 is ca. 5%, while it increases to over 75% in phase 2. Moreover, a merger can be prohibited only after phase 2.




Fig. 3. Effective merger control: (a) rivals and (b) merging firms.

ex-ante probability of clearance:

$$\Pi_{ij}^{D*} = (\Pi_{ij}^{P2} + \Pi_{ij}^{P1}) / (1 - \Pr[\text{action}_i | I_A]) \tag{A.3}$$

Appendix C. Graphical representation of our framework

Fig. 3 should help to clarify our predictions in diagrams representing the announcement rents on the x-coordinate and the decision rents on the y-coordinate. In part (a) we describe the prediction for rivals. Consider a merger 1, where efficiency and market power effects on rivals exactly cancel each other out (i.e. $\Pi^{MP} = -\Pi^{efficiencies}$), so that measured abnormal returns around the merger announcement are zero (point A^1). If this merger is blocked, the decision's effect on rivals should also be zero, since there is no net rent to be reversed. On the contrary, for this merger an effective remedy would rip out only the market power rents ($-\Pi^{MP}$), leading to a negative shift (i.e. intercept) due to the decision (movement to R^1). Consider now the clearly anticompetitive merger 2. The market power effect is larger than the efficiency effect, so the starting point is A^2 . If this merger is blocked, both the market power and the efficiency rents are reversed: we move down to B^2 , by the amount of the net effect $-(\Pi^{MP} + \Pi^{efficiencies})$. In the case of remedies, an effective decision takes away the market power effect still maintaining the efficiency effect. Therefore we move further down to point R^2 . By tracing out all possible mergers, we get the predicted regression lines for the case of prohibitions and effective remedies. In the former, the slope is equal to -1 ; in the latter, it is still negative but less steep than -1 .⁴⁰

In part (b) we describe the situation for the merging firms. First, notice that here the origin represents a merger that has neither a market power nor an efficiency effect on merging firms' profitability. Furthermore, in this case an effective action should not take away any rent since the merger does not create any. Therefore, both regression lines for remedies and prohibitions should run through the origin. We now consider merger 1 again, which has a positive announcement effect

⁴⁰ The negative slope hinges on the assumption that the anticompetitive effect monotonically increases with the net effect, i.e. that anticompetitive and efficiency effects are not perfectly negatively correlated.

consisting of the sum of the positive market power rents (Π^{MP}) and the positive rents due to increased efficiency ($\Pi^{efficiencies}$). The starting point is therefore A^1 . If this merger is blocked, both kinds of rents are destroyed and we move down to point B^1 . If effective remedies are imposed, only the market power rents are ripped out by the antitrust action and we move down to point R^1 . The same mechanism applies to merger 2. As with rivals, we observe for the merging firms, too, that in the case of blocking the slope of the regression line should be -1 , while in the case of remedies it should be negative yet, in absolute terms, smaller than -1 .⁴¹

References

- Acharya, S., 1993. Value of latent information: alternative event study methods. *Journal of Finance* 48 (1), 363–385.
- Aktas, N., de Bodt, E., Roll, R., 2004. Market response to European regulation of business combinations. *Journal of Financial and Quantitative Analysis* 39 (4), 731–757.
- Aktas, N., de Bodt, E., Roll, R., 2007. European M&A regulation is protectionist. *Economic Journal* 117, 1096–1121.
- Akdogu, E., Harford, J., Moeller, S.B., 2005. Value Creation and Merger Waves. Southern Methodist University, Mimeo.
- Andrade, G., Mitchell, M., Stafford, E., 2001. New evidence and perspectives on mergers. *Journal of Economic Perspectives* 15, 103–120.
- Baker, J.B., 2003. The case for antitrust enforcement. *Journal of Economic Perspectives* 17, 27–50.
- Banerjee, A., Eckard, W.E., 1998. Are mega-mergers anti-competitive? Evidence from the first great merger wave. *Rand Journal of Economics* 29, 803–827.
- Cabral, L.M.B., 2003. Horizontal mergers with free-entry: why cost efficiencies may be a weak defense and asset sales a poor remedy. *International Journal of Industrial Organization* 21, 607–623.
- Carlton, D., Gertner, R., 2003. Intellectual property, antitrust and strategic behavior. In: Jaffee, Adam, Lerne, Joshua (Eds.), *Innovation Policy and the Economy*, vol. 3. MIT Press, Cambridge, MA.
- Clougherty, J., Duso, T., 2009. The impact of horizontal mergers on rivals: gains to being left outside a merger. *Journal of Management Studies* 46 (8), 1365–1395.
- Crandall, R.W., Winston, C., 2003. Does antitrust policy improve consumer welfare? Assessing the evidence. *Journal of Economic Perspectives* 17, 3–26.
- Davies, S., Lyons, B., 2007. *Merger and Merger Remedies in the EU. Assessing the Consequences for Competition*. Edward Elgar Publishing, MA, Northampton.
- DG Comp—European Commission, 2005. Merger Remedies Study Available from: <http://ec.europa.eu/comm/competition/mergers/others/remedies_study.pdf>.
- Deneckere, R., Davidson, C., 1985. Incentives to form coalitions with Bertrand competition. *RAND Journal of Economics* 16 (4), 473–486.
- Duso, T., Neven, D., Röller, L.-H., 2007a. The political economy of European merger control: evidence using stock market data. *Journal of Law and Economics* 50 (3), 455–489.
- Duso, T., Gugler, K., Yurtoglu, B., 2007b. EU merger remedies: an empirical assessment. In: Stennek, J., Ghosal, V. (Eds.), *The Political Economy of Antitrust, Contributions to Economic Analysis*. North-Holland, Elsevier, Amsterdam, pp. 303–348.
- Duso, T., Gugler, K., Yurtoglu, B., 2010. Is the event study methodology useful for merger analysis: a comparison of stock market and accounting data. *International Review of Law and Economics* 30 (2), 186–192.
- Eckbo, B.E., 1983. Horizontal mergers, collusion, and stockholder wealth. *Journal of Financial Economics* 11, 241–273.
- Eckbo, B.E., 1989. The role of stock market studies in formulating antitrust policy toward mergers: comment. *Quarterly Journal of Business and Economics* 28, 22–38.
- Eckbo, B.E., 1992. Mergers and the value of antitrust deterrence. *Journal of Finance* 47 (3), 1005–1029.
- Eckbo, B.E., Wier, P., 1985. Antimerger policy under the Hart–Scott–Rodino act: a re-examination of the market power hypothesis. *Journal of Law and Economics* 28, 119–149.
- Ellert, James, 1976. Mergers, antitrust law enforcement and stockholder returns. *Journal of Finance* 31 (2), 715–732.
- European Commission, 2001. Commission Notice on remedies acceptable under Council Regulation (EEC) No 4064/89 and under Commission Regulation (EC) No 447/98. *Official Journal C* 68, 02.03.2001, p. 3.
- Elzinga, K., 1969. The antimerger law: pyrrhic victories? *Journal of Law and Economics* 43, 52.
- Evans, D.S., Salinger, M., 2002. Competition thinking at the European commission: lessons from the Aborted GE/Honeywell Merger. *George Mason Law Review* 10, 489–532.
- Farrell, J., 2003. Negotiation and merger remedies: some problems. In: Leveque, F., Shelanski, H. (Eds.), *Merger Remedies in American and European Union Competition Law*. Edward Elgar Publishing, MA, Northampton.
- Farrell, J., Shapiro, C., 1990. Horizontal mergers: an equilibrium analysis. *American Economic Review*, 107–126 (March).
- Fee, C.E., Thomas, S., 2004. Sources of gains in horizontal mergers: evidence from customer, supplier and rival firms. *Journal of Financial Economics* 74, 423–460.
- Fridolfsson, S.O., Stennek, J., 2005. Why mergers reduce profits and raise share prices. *Journal of the European Economic Association* 3, 1083–1104.
- Fridolfsson, S.O., Stennek, J., 2009. Industry concentration and welfare: on the use of stock market evidence from horizontal mergers. *Economica*, 1–19.
- Federal Trade Commission (FTC), 1999. A Study of the Commission's Divestiture Process Available from: <<http://www.ftc.gov/opa/1999/08/divestreport.htm>>.
- Gugler, K., Mueller, D.C., Yurtoglu, B.B., Zulehner, C., 2003. The effects of mergers: an international comparison. *International Journal of Industrial Organization* 21 (5), 625–653.
- Gugler, K., Mueller, D.C., Yurtoglu, B.B., 2006. The Determinants of Merger Waves (WZB DP SP II 2006-01).
- Gugler, K., Siebert, R., 2007. Market power versus efficiency effects of mergers and research joint ventures: evidence from the semiconductor industry. *Review of Economics and Statistics* 89 (4), 645–659.
- Jovanovic, B., Rousseau, P.L., 2002. The Q-theory of mergers. *American Economic Review, Papers and Proceedings* 92 (2), 198–204.
- Kim, E.H., Singal, V., 1993. Mergers and market power: evidence from the airline industry. *American Economic Review* 83 (3), 549–569.
- Lyons, Bruce, 2004. Reform of European merger policy. *Review of International Economics* 12 (2), 246–261.
- Malatesta, P.H., Thompson, R., 1985. Partially anticipated events: a model of stock price reactions with an application to corporate acquisitions. *Journal of Financial Economics* 14, 237–250.
- McAfee, R.P., Williams, M.A., 1988. Can event studies detect anticompetitive mergers? *Economic Letters* 28, 199–203.
- Mitchell, M.L., Mulherin, J.H., 1996. The impact of industry shocks on takeover and restructuring activity. *Journal of Financial Economics* 41, 193–229.
- Motta, M., Polo, M., Vasconcelos, H., 2003. Merger remedies in the European Union: an overview. In: Leveque, F., Shelanski, H. (Eds.), *Merger Remedies in American and European Union Competition Law*. Edward Elgar Publishing, MA, Northampton.

⁴¹ In Fig. 3b, we blanked out the possibility of non-profitable mergers. The fact that mergers happen which reduce the efficiency and profits of merging firms cannot be well explained by standard industrial organization models (for an exception, see Fridolfsson and Stennek, 2005). Nevertheless, there is overwhelming evidence that these managerial mergers do take place (see e.g. Gugler et al., 2003). Predictions for an effective merger control in this case are difficult to spell out.

- Nocke, V., Whinston, M.D., 2010. Dynamic merger review. *Journal of Political Economy* 118 (6), 1200–1251.
- Office of Fair Trading (OFT), 2005. Ex Post Evaluation of Mergers Available from: <http://www.offt.gov.uk/shared_offt/reports/comp_policy/oft767.pdf>.
- Organisation for Economic Cooperation and Development (OECD), 2004. Merger remedies DAF/COMP(2004)21. Available from: <<http://www.oecd.org/dataoecd/61/45/34305995.pdf>>.
- Pfunder, M.R., Plaine, D.J., Whittemore, A.M., 1972. Compliance with divestiture orders under section 7 of the Clayton Act. *Antitrust Bulletin* 17 (1), 19–180.
- Rogowsky, Robert A., 1986. The economic effectiveness of section 7 relief. *Antitrust Bulletin*, 187–233.
- Salant, S.W., Switzer, S., Reynolds, R.J., 1983. Losses from horizontal merger: the effects of an exogenous change in industry structure on Cournot–Nash equilibrium. *Quarterly Journal of Economics* 98, 185–199.
- Scholes, M., Williams, J., 1977. Estimating beta from non-synchronous data. *Journal of Financial Economics* 5, 309–327.
- Seldeslachts, J., Clougherty, J., Barros, P.P., 2009. Settle for now but block for tomorrow: the deterrence effects of merger policy tools. *Journal of Law and Economics* 52 (3), 607–634.
- Shahrur, H., 2005. Industry structure and horizontal takeovers: analysis of wealth effects on rivals, suppliers and corporate customers. *Journal of Financial Economics* 76, 61–98.
- Simpson, John David, 2001. did may company's acquisition of associated dry goods corporation reduce competition? An event study analysis. *Review of Industrial Organization* 18, 351–362.
- Song, M.H., Walkling, R.A., 2000. Abnormal returns to rivals of acquisition targets: a test of the acquisition probability hypothesis. *Journal of Financial Economics* 55, 143–171.
- Sørgard, L., 2009. Optimal merger policy. *Journal of Industrial Economics* 57 (3), 438–456.
- Stigler, G.J., 1950. Monopoly and oligopoly by merger. *American Economic Review* 40 (2), 23–34.
- Stillman, R., 1983. Examining antitrust policy towards horizontal mergers. *Journal of Financial Economics* 11, 225–240.
- U.S. Department of Justice, 2004. Antitrust Division Policy Guide to Merger Remedies. <http://www.justice.gov/atr/public/guidelines/205108.htm>.
- Werden, Gregory J., Williams, Michael A., 1989. The role of stock market studies in formulating antitrust policy toward horizontal mergers. *Quarterly Journal of Business and Economics* 28, 3–21.